tranexamic acid has been researched along with Complication, Postoperative in 218 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dexamethasone and tranexamic acid are used to decrease post-rhinoplasty periorbital edema and ecchymosis." | 9.27 | Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis. ( Bijani, A; Ghanepur, H; Ghassemi, A; Khakzad, M; Mehdizadeh, M; Mehrbakhsh, Z; Mir, M; Moghadamnia, A; Nekoohesh, L, 2018) |
| "The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)." | 9.20 | The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015) |
| "To systematically review the literature to compare the efficacy and safety of tranexamic acid (TXA) as a means to minimize hemarthrosis-related complications after arthroscopic procedures of the knee, hip, and shoulder." | 9.12 | Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies. ( Belk, JW; Dragoo, JL; Houck, DA; McCarty, EC; Savoie, FH; Thon, SG, 2021) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 9.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 9.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 9.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "The influence of tranexamic acid on the intraocular pressure and central corneal thickness has been examined by means of a double-blind trial in patients with glaucoma simplex." | 9.04 | A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. ( Bramsen, T, 1978) |
| "To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty." | 9.01 | Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019) |
| "To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty." | 8.98 | Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018) |
| "Previous studies have shown that systemic tranexamic acid reduces bleeding during soft tissue surgeries and reduces postoperative ecchymosis and edema experienced by surgical patients." | 8.02 | Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas. ( Choi, YJ; Kim, WS; Lee, GY; Lee, HJ; Park, HJ, 2021) |
| "The aim of the present study is to examine the effect of local administration of tranexamic acid (TXA) through lateral osteotomy line on postoperative periorbital edema and ecchymosis." | 8.02 | The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty. ( Bezgin, SÜ; Çakabay, T; Çelebi, Ş; İpek, HD, 2021) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 7.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 7.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 7.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 5.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| "High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications." | 5.69 | Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. ( Chai, M; He, Z; Wu, X; Xia, L; Yang, X; Zhang, J, 2023) |
| "To assess the efficacy and safety of single-dose tranexamic acid on the blood transfusion rate and outcomes of patients with complex kidney stones undergoing percutaneous nephrolithotomy (PCNL)." | 5.51 | Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial. ( Batagello, CA; Coelho, RF; Danilovic, A; Marchini, GS; Mazzucchi, E; Miller, AW; Monga, M; Nahas, WC; Srougi, M; Torricelli, FCM; Vicentini, FC, 2022) |
| "Tranexamic acid (TXA) is a commonly antifibrinolytic agent in cardiac surgeries with cardiopulmonary bypass (CPB), however, there is concern that it might increase incidence of stroke after cardiac surgery." | 5.46 | Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. ( Huo, YF; Sun, K; Sun, LH; Xing, XF; Yan, M; Yu, LN; Yu, YX; Zhang, FJ; Zhou, ZF, 2017) |
| "Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3." | 5.38 | Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 5.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 5.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
| "All patients with seizures did not have permanent neurological abnormalities." | 5.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
| "We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period." | 5.30 | OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019) |
| "Dexamethasone and tranexamic acid are used to decrease post-rhinoplasty periorbital edema and ecchymosis." | 5.27 | Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis. ( Bijani, A; Ghanepur, H; Ghassemi, A; Khakzad, M; Mehdizadeh, M; Mehrbakhsh, Z; Mir, M; Moghadamnia, A; Nekoohesh, L, 2018) |
| "The aim of this randomized double-blind study was to evaluate the efficacy of Tranexamic acid (TXA) on intraoperative bleeding, postoperative eyelid edema, and postoperative periorbital ecchymosis in rhinoplasty." | 5.24 | Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study. ( Chavoshzadeh, MA; Ghavimi, MA; Ghoreishizadeh, A; Taheri Talesh, K; Zarandi, A, 2017) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "The aim of this study was to investigate the efficacy of tranexamic acid (TA) and methylprednisolone on periorbital edema, ecchymosis, and intraoperative bleeding in patients who underwent open septorhinoplasty (oSRP)." | 5.20 | The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty. ( Akyiğit, A; Düzer, S; Orhan, İ; Polat, C; Sakallioğlu, Ö; Soylu, E, 2015) |
| "There was no statistically significant reduction in bleeding volume with the use of tranexamic acid (mean ± standard deviation, 135." | 5.16 | Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. ( Brum, MR; Castro, SF; Lima, LH; Lubianca Neto, JF; Machado, GM; Miura, MS, 2012) |
| "To systematically review the literature to compare the efficacy and safety of tranexamic acid (TXA) as a means to minimize hemarthrosis-related complications after arthroscopic procedures of the knee, hip, and shoulder." | 5.12 | Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies. ( Belk, JW; Dragoo, JL; Houck, DA; McCarty, EC; Savoie, FH; Thon, SG, 2021) |
| "This study aimed to evaluate the efficacy and safety of using high-dose intravenous tranexamic acid (TXA) to reduce blood loss in idiopathic scoliosis surgery." | 5.12 | The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis. ( Chen, JC; Lin, L; Na, XQ; Qu, QC; Ruan, TY; Shrestha, IK; Si, YY; Tan, M; Tao, JP, 2021) |
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 5.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "The contribution of fibrinolysis to postoperative bleeding after cardiopulmonary bypass led to routine use of tranexamic acid, a potent antifibrinolytic drug, for a period of time." | 5.07 | Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. ( Abdelnoor, M; Am Holen, E; Ovrum, E; Oystese, R; Ringdal, ML, 1993) |
| "One hundred patients with a verified subarachnoid haemorrhage were studied in a double blind, placebo-controlled trial at a single centre to determine the value and relative risks of tranexamic acid (TXA) in the management of ruptured intracranial aneurysms." | 5.06 | Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. ( Hitchcock, ER; Meyer, CH; Tsementzis, SA, 1990) |
| "A randomized, controlled clinical trial was carried out to study the effect of tranexamic acid (AMCA, trans-AMCHA) in prevention of early rebleeding after proven rupture of an intracranial aneurysm." | 5.04 | Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. ( Fodstad, H; Liliequist, B; Schannong, M; Thulin, CA, 1978) |
| "The influence of tranexamic acid on the intraocular pressure and central corneal thickness has been examined by means of a double-blind trial in patients with glaucoma simplex." | 5.04 | A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex. ( Bramsen, T, 1978) |
| "To systematically examine the role of tranexamic acid in reducing intraoperative blood loss and postoperative edema and ecchymosis among patients undergoing primary elective rhinoplasty." | 5.01 | Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis. ( Bezuhly, M; McGuire, C; Nurmsoo, S; Samargandi, OA, 2019) |
| "To investigate the results of tranexamic acid use to reduce intraoperative bleeding, postoperative eyelid edema, and periorbital ecchymosis in rhinoplasty." | 4.98 | Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis. ( de Aguiar Menezes, MV; de Souza Dantas, R; de Vasconcellos, SJA; do Nascimento-Júnior, EM; Martins-Filho, PRS; Tavares Mendes, ML, 2018) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "The purpose of this study was to explore efficacy of locally injected tranexamic acid (TXA) at a concentration of 1 mg/mL for reduction perioperative bleeding and postoperative complications in subcutaneous tumor excisions." | 4.31 | Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center. ( Chang, YJ; Lin, HC; Lin, YH; Wang, PL, 2023) |
| "The aim of the present study is to examine the effect of local administration of tranexamic acid (TXA) through lateral osteotomy line on postoperative periorbital edema and ecchymosis." | 4.02 | The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty. ( Bezgin, SÜ; Çakabay, T; Çelebi, Ş; İpek, HD, 2021) |
| "The specific method and dose of tranexamic acid (TXA) topically applied for intertrochanteric fractures have not been well established." | 4.02 | Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA. ( He, J; Huang, T; Wei, H; Xia, M; Xian, S; Xiao, Q; Xu, W, 2021) |
| "Previous studies have shown that systemic tranexamic acid reduces bleeding during soft tissue surgeries and reduces postoperative ecchymosis and edema experienced by surgical patients." | 4.02 | Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas. ( Choi, YJ; Kim, WS; Lee, GY; Lee, HJ; Park, HJ, 2021) |
| " A standard blood management protocol that consisted of hypotensive anesthesia, local and systemic administration of tranexamic acid (TXA) and intraoperative cell salvage was applied to all patients." | 3.96 | Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients? ( Çıtak, M; Gehrke, T; Köse, Ö; Levent, A; Linke, P, 2020) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 3.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 3.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| "Geriatric hip fracture patients are particularly susceptible to blood loss and venous thromboembolism (VTE) during hemiarthroplasty, yet relatively few studies have examined the safety and efficacy of tranexamic acid (TXA) in these patients." | 3.91 | Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study. ( Chen, G; Hu, Q; Huang, Q; Pei, F; Xie, J; Zhou, Z, 2019) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 3.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "The effects of locally deposited fibrin and of tranexamic acid-induced antifibrinolysis on forming granulation tissue were studied in the light of a recently developed method for treatment of postoperative fistulas by occlusion with a fibrin clot." | 3.67 | Effects of tranexamic acid and local fibrin deposition of fibrinolysis and granulation tissue formation in preformed cavities. ( Hedelin, H; Peterson, HI; Pettersson, S; Teger-Nilsson, AC, 1984) |
| " Prophylaxis against angioneurotic oedema using danazol and tranexamic acid is described and the resultant complication of mesenteric venous thrombosis reported." | 3.67 | Acquired C1 esterase inhibitor deficiency. ( Coulson, IH; Findley, IL; Gould, TR; Razis, PA, 1986) |
| "Tranexamic acid (TXA) has been hypothesized as an oral agent to avoid CSDH progression and/or recurrence." | 3.30 | Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial. ( de Freitas, PVV; de Oliveira, MF; de Paula, MVCT; Melo, MM; Pahl, FH; Ribeiro, BDC; Rotta, JM, 2023) |
| "Secondary outcome criteria were postoperative pain, intraarticular effusion (measured by ultrasound), range of motion (ROM) at discharge, peri- and postoperative complications and the KOOS PS (pre- and postoperatively at 1 year follow up)." | 3.11 | Use of tranexamic acid in medial open wedge high tibial osteotomy. ( Bentzin, M; Bierke, S; Häner, M; Park, HU; Petersen, W, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent, which reduces bleeding in numerous scenarios, however, its prophylactic use in mitigating post-TBLB bleeding has not been investigated." | 2.94 | Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial. ( Abu Rmeileh, A; Abutbul, A; Berkman, N; Cohen Goichman, P; Fridlender, ZG; Huszti, E; Kuint, R; Levy, L; Shriki, O, 2020) |
| "Deep venous thrombosis (DVT) and pulmonary embolism (PE) events were monitored and recorded." | 2.94 | Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion. ( Bai, T; Huang, Y; Li, J; Liu, Y; Wang, L, 2020) |
| "Tranexamic acid (TXA) has long been used to reduce blood loss associated with total knee arthroplasty (TKA)." | 2.90 | Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial. ( Bernaitis, N; Dare, W; King, L; Randle, R, 2019) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug." | 2.90 | Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. ( Baaklini, LR; Cross, JR; Fields, KG; Jules-Elysee, KM; Mayman, DJ; McLawhorn, AS; Pickard, AJ; Qin, W; Sculco, TP; Su, EP; Tseng, A, 2019) |
| " However, the optimal oral dosage regimen to achieve maximum blood-loss reduction remains unclear." | 2.90 | Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. ( Luo, ZY; Pei, FX; Wang, D; Wang, HY; Zeng, WN; Zhou, ZK, 2019) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| "Tranexamic acid was given at the end of the operation and 3 hours later." | 2.69 | Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. ( Benoni, G; Fredin, H; Lethagen, S; Nilsson, P, 2000) |
| "Tranexamic acid was found as effective as aprotinin on platelets function." | 2.67 | [The use of antifibrinolytics in heart surgery. 3 prospective studies]. ( Benmosbah, L; Boughenou, F; Cousin, MT; Madi-Jebara, S; Massonnet-Vastel, S, 1993) |
| " It was concluded that patients on oral anticoagulants can undergo oral surgery within the therapeutic range without reducing the dosage of anticoagulants, provided that local antifibrinolytic treatment with tranexamic acid solution is instituted." | 2.67 | Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. ( Alander, U; Blombäck, M; Hall, G; Ramström, G; Sindet-Pedersen, S, 1993) |
| "Fifteen extraction sockets packed with a new drug combination which includes a local anaesthetic (cincain chloride), a local antiseptic (tri-iodomethane) and two drugs with a potent antifibrinolytic activity (tranexamic acid and propyl-hydroxy-benzoic acid) in an absorbable gelatin sponge (Gelfoam) as a vehicle, were histologically assessed with special reference to the parameters related to wound healing." | 2.65 | The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report. ( Syrjänen, KJ; Syrjänen, SM, 1981) |
| "placebo on development of alveolitis sicca dolorosa (ASD) had as preoperative registration requirements age, sex, use of oral contraceptives, menstrual cycle, smoking, and degree of impaction at time of operation." | 2.65 | Tranexamic acid in alveolar sockets in the prevention of alveolitis sicca dolorosa. ( Gersel-Pedersen, N, 1979) |
| "Tranexamic acid appears to be an effective and well-tolerated agent for reduction of blood loss caused by local hyperfibrinolysis." | 2.64 | [Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy]. ( Castelli, G; Vogt, E, 1977) |
| "Tranexamic acid (TXA) is an anti-fibrinolytic agent successfully preventing blood loss when using intravenously (IV) in total hip arthroplasty (THA) and total knee arthroplasty (TKA)." | 2.58 | Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. ( Gong, G; Han, N; Han, X; Liu, M, 2018) |
| "81) or and incidence of adverse effects such as infection (P = 0." | 2.53 | Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis. ( Jiang, X; Ma, JX; Ma, XL, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding in mortality risk situations such as trauma." | 2.52 | Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis. ( Díaz Quijano, DM; Pinzón-Florez, CE; Vélez Cañas, KM, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that has been shown to reduce blood loss following surgery." | 1.91 | Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection. ( Foster, D; Garner, H; Goulding, K; Houdek, M; Sebro, R; Spaulding, AC; Stanborough, R; Wilke, B, 2023) |
| "Spinal surgery for scoliosis has been performed in selected patients with single ventricle physiology at a single institution without mortality for 25 years." | 1.62 | Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology. ( Cohen, LL; Emans, JB; Hedequist, DJ; Marshall, AC; Przybylski, R, 2021) |
| "Tranexamic acid (TXA) has proven to be safe in elective and traumatic femoral hemiarthroplasty; however, its use has not been investigated in oncologic patients." | 1.62 | Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease. ( Houdek, MT; Owen, A; Rose, PS; Wellings, EP; Wyles, CC; Yuan, BJ, 2021) |
| "Tranexamic acid (TXA) has proven to be effective in reducing the blood loss associated with total knee arthroplasty (TKA) in patients with osteoarthritis." | 1.62 | Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China. ( Huang, Q; Huang, W; Lei, Y; Pei, F; Xie, J, 2021) |
| "PURPOSE OF THE STUDY Heterotopic ossification is a frequent and a well-known complication after elective primary total hip arthroplasty." | 1.62 | [Tranexamic Acid Reduces the Incidence of Heterotopic Ossifications after Elective Primary Total Hip Arthroplasty]. ( Debre, J; Dupal, J; Štěpán, Z, 2021) |
| "Tranexamic acid (TXA) is a medication that has been shown to decrease blood loss and risk of blood transfusion in total knee and total hip arthroplasty." | 1.56 | Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty. ( Falcon, S; Haleem, AM; Hollabaugh, K; Luick, L; Ringus, V; Steinmetz, RG; Stoner, J; Tkach, S, 2020) |
| "Tranexamic acid use in craniosynostosis surgery has increased dramatically since 2010." | 1.56 | Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe? ( Bennett, WE; Cook, JA; Danforth, RM; Gerety, PA; Tholpady, SS, 2020) |
| "Tranexamic acid was administered in 54 (60." | 1.48 | Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. ( Bakkum-Gamez, JN; Borah, BJ; Cliby, WA; DeJong, SR; Dowdy, SC; Halverson, JW; Higgins, AA; Jankowski, CJ; Kor, DJ; Moriarty, JP; Otto, HA; Wallace, SK; Weaver, AL; Weinhold, MR, 2018) |
| "Tranexamic acid (TXA) is a commonly antifibrinolytic agent in cardiac surgeries with cardiopulmonary bypass (CPB), however, there is concern that it might increase incidence of stroke after cardiac surgery." | 1.46 | Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. ( Huo, YF; Sun, K; Sun, LH; Xing, XF; Yan, M; Yu, LN; Yu, YX; Zhang, FJ; Zhou, ZF, 2017) |
| "Of a total of 259 patients with craniosynostosis, 187 had nonsyndromic single-suture involvement; 69 of these patients (36." | 1.43 | Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis. ( Diggs, B; Esmonde, N; Gries, H; Koh, J; Kuang, AA; Martin, DT; Schreiber, M; Selden, NR, 2016) |
| "Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis." | 1.42 | Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction. ( Claiborne, JR; Couture, DE; Crantford, JC; David, LR; Ririe, DG; Thompson, JT; Wood, BC, 2015) |
| "Tranexamic acid (TXA) is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin." | 1.42 | TXA in combat casualty care--does it adversely affect extremity reconstruction and flap thrombosis rates? ( Campbell, P; Fleming, M; Jessie, E; Lucas, DJ; Rodriguez, C; Sabino, J; Valerio, IL, 2015) |
| "Changes in the hemostasis system in choledocholithiasis, taking into account the obturation jaundice severity and possibility of the correction conduction, using miniinvasive operative interventions, were studied." | 1.40 | [Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions]. ( Tkachenko, AI, 2014) |
| "The seizures were likely due to a total dose of 8 g of tranexamic acid (TXA) administered intraoperatively." | 1.39 | [A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement]. ( Ichikawa, J; Kodaka, M; Komori, M; Kubota, S; Nakano, K; Nishiyama, K; Sato, N, 2013) |
| " Future tranexamic acid trials should assess the blood-conserving effect of tranexamic acid at a lower dosage and specifically monitor for seizure occurrence." | 1.38 | High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. ( Dagenais, F; Dionne, S; Kalavrouziotis, D; Mohammadi, S; Voisine, P, 2012) |
| "Compared to the non-seizure group, seizure patients had an increased rate of postoperative neurological complications, defined as delirium and/or stroke (3." | 1.38 | Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. ( Ariano, RE; Grocott, HP; Jacobsohn, E; Leake, J; Manji, JS; Manji, RA; Menkis, AH, 2012) |
| "Postoperative seizures occurred significantly more frequently in TXA patients (7." | 1.37 | Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid. ( Breuer, T; Gertler, R; Knorr, J; Lange, R; Macguill, M; Martin, K; Tassani, P; Wiesner, G, 2011) |
| "All patients with seizures did not have permanent neurological abnormalities." | 1.36 | High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. ( Burt, C; Chu, M; Falter, F; Granton, J; Murkin, JM; Young, B, 2010) |
| " Further confirmatory prospective studies evaluating the efficacy and safety profile of TXA are urgently needed to find a safe dosage for this antifibrinolytic drug." | 1.36 | Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. ( Martiny, V; Rosenthal, C; Sander, M; Spies, CD; von Heymann, C; Wernecke, KD, 2010) |
| "The exact mechanism of TxA-induced seizures is thought to be via inhibition of gamma-aminobutyric acid receptors in neurons." | 1.36 | Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series. ( Almeida, A; Bell, D; Marasco, S; Rowland, M, 2010) |
| " The protamine dose necessary to reverse heparin after extracorporeal circulation (ECC) was assessed in ten patients from individual heparin dose-response curves (HDR group)." | 1.27 | The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. ( Hatteland, K; Ottesen, S; Stormorken, H, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (13.30) | 18.7374 |
| 1990's | 18 (8.26) | 18.2507 |
| 2000's | 13 (5.96) | 29.6817 |
| 2010's | 105 (48.17) | 24.3611 |
| 2020's | 53 (24.31) | 2.80 |
| Authors | Studies |
|---|---|
| Petersen, W | 1 |
| Bentzin, M | 1 |
| Bierke, S | 1 |
| Park, HU | 1 |
| Häner, M | 1 |
| Chang, MJ | 1 |
| Shin, JY | 1 |
| Yoon, C | 1 |
| Kim, TW | 1 |
| Chang, CB | 1 |
| Kang, SB | 1 |
| Peng, L | 1 |
| Zeng, J | 2 |
| Zeng, Y | 2 |
| Wu, Y | 1 |
| Yang, J | 2 |
| Shen, B | 1 |
| Wang, J | 3 |
| Zhang, Z | 1 |
| Li, J | 6 |
| Huang, B | 1 |
| Jiang, Z | 1 |
| Pan, Y | 1 |
| He, T | 1 |
| Hu, Y | 1 |
| Wang, L | 2 |
| Moore, AD | 1 |
| Smith, BR | 1 |
| O'Leary, RJ | 1 |
| Hoch, CP | 1 |
| Gross, CE | 1 |
| Scott, DJ | 1 |
| Mei, J | 1 |
| Kim, CH | 1 |
| Hwang, J | 1 |
| Lee, SJ | 1 |
| Yoon, PW | 1 |
| Yoon, KS | 1 |
| Lech, P | 1 |
| Michalik, M | 1 |
| Waczyński, K | 1 |
| Osowiecka, K | 1 |
| Dowgiałło-Gornowicz, N | 1 |
| Li, Y | 1 |
| Huang, Y | 2 |
| Zhang, H | 2 |
| Ye, P | 1 |
| Deng, P | 1 |
| Chen, J | 3 |
| Qi, X | 1 |
| Feng, W | 1 |
| Yang, X | 1 |
| Chai, M | 1 |
| Xia, L | 1 |
| He, Z | 1 |
| Wu, X | 1 |
| Zhang, J | 2 |
| de Paula, MVCT | 1 |
| Ribeiro, BDC | 1 |
| Melo, MM | 1 |
| de Freitas, PVV | 1 |
| Pahl, FH | 1 |
| de Oliveira, MF | 1 |
| Rotta, JM | 1 |
| Foster, D | 1 |
| Sebro, R | 1 |
| Garner, H | 1 |
| Stanborough, R | 1 |
| Spaulding, AC | 2 |
| Goulding, K | 1 |
| Houdek, M | 1 |
| Wilke, B | 1 |
| Chang, YJ | 1 |
| Lin, YH | 1 |
| Wang, PL | 1 |
| Lin, HC | 1 |
| Zhao, M | 1 |
| Geng, X | 1 |
| Wang, C | 1 |
| Zeng, L | 1 |
| Tian, H | 1 |
| Hulde, N | 2 |
| Zittermann, A | 2 |
| Deutsch, MA | 2 |
| von Dossow, V | 2 |
| Gummert, JF | 2 |
| Koster, A | 2 |
| Sukeik, M | 1 |
| Alshryda, S | 1 |
| Powell, J | 1 |
| Haddad, FS | 1 |
| King, L | 1 |
| Randle, R | 1 |
| Dare, W | 1 |
| Bernaitis, N | 1 |
| Bradley, KE | 1 |
| Ryan, SP | 1 |
| Penrose, CT | 1 |
| Grant, SA | 1 |
| Wellman, SS | 1 |
| Attarian, DE | 1 |
| Green, CL | 1 |
| Risoli, T | 1 |
| Bolognesi, MP | 1 |
| Gerstein, NS | 1 |
| Cushnyr, BW | 1 |
| Petersen, TR | 1 |
| Siegel, D | 1 |
| Xu, Y | 1 |
| Sun, S | 1 |
| Feng, Q | 1 |
| Zhang, G | 1 |
| Dong, B | 1 |
| Wang, X | 2 |
| Guo, M | 1 |
| Taunton, MJ | 1 |
| Simon, RP | 1 |
| Oromendia, C | 1 |
| Sanso, LM | 1 |
| Ramos, LG | 1 |
| Rajwani, K | 1 |
| Jules-Elysee, KM | 1 |
| Tseng, A | 1 |
| Sculco, TP | 1 |
| Baaklini, LR | 1 |
| McLawhorn, AS | 1 |
| Pickard, AJ | 1 |
| Qin, W | 1 |
| Cross, JR | 1 |
| Su, EP | 1 |
| Fields, KG | 1 |
| Mayman, DJ | 1 |
| Chen, SH | 1 |
| Chen, JY | 2 |
| Wong, TH | 1 |
| Buechel, F | 1 |
| Wu, MH | 1 |
| Hines, JT | 1 |
| Petis, SM | 1 |
| Amundson, AW | 1 |
| Pagnano, MW | 3 |
| Sierra, RJ | 1 |
| Abdel, MP | 2 |
| An, YZ | 1 |
| Xu, MD | 1 |
| An, YC | 1 |
| Liu, H | 2 |
| Zheng, M | 1 |
| Jiang, DM | 1 |
| Lloyd, TD | 1 |
| Neal-Smith, G | 1 |
| Fennelly, J | 1 |
| Claireaux, H | 1 |
| Bretherton, C | 1 |
| Carr, AJ | 1 |
| Murphy, M | 1 |
| Kendrick, BJ | 1 |
| Palmer, AJR | 1 |
| Wan, Y | 1 |
| Steinmetz, RG | 1 |
| Luick, L | 1 |
| Tkach, S | 1 |
| Falcon, S | 1 |
| Stoner, J | 1 |
| Hollabaugh, K | 1 |
| Ringus, V | 1 |
| Haleem, AM | 1 |
| Biboulet, P | 1 |
| Motais, C | 1 |
| Pencole, M | 1 |
| Karam, O | 1 |
| Dangelser, G | 1 |
| Smilevitch, P | 1 |
| Maissiat, G | 1 |
| Capdevila, X | 1 |
| Bringuier, S | 1 |
| Weissler, JM | 1 |
| Banuelos, J | 1 |
| Jacobson, SR | 1 |
| Manrique, OJ | 1 |
| Nguyen, MT | 1 |
| Harless, CA | 1 |
| Tran, NV | 1 |
| Martinez-Jorge, J | 1 |
| Bai, T | 1 |
| Liu, Y | 2 |
| Wang, HY | 3 |
| Yuan, MC | 1 |
| Pei, FX | 2 |
| Zhou, ZK | 2 |
| Liao, R | 1 |
| Yang, L | 1 |
| Jia, X | 1 |
| Kang, J | 1 |
| Levent, A | 1 |
| Köse, Ö | 1 |
| Linke, P | 1 |
| Gehrke, T | 1 |
| Çıtak, M | 1 |
| Kuint, R | 1 |
| Levy, L | 1 |
| Cohen Goichman, P | 1 |
| Huszti, E | 1 |
| Abu Rmeileh, A | 1 |
| Shriki, O | 1 |
| Abutbul, A | 1 |
| Fridlender, ZG | 1 |
| Berkman, N | 1 |
| Ashkenazi, I | 1 |
| Schermann, H | 1 |
| Gold, A | 1 |
| Gurel, R | 1 |
| Chechik, O | 1 |
| Warschawski, Y | 1 |
| Schwarzkopf, R | 1 |
| Snir, N | 1 |
| Sun, C | 1 |
| Zhang, X | 2 |
| Chen, L | 2 |
| Deng, J | 2 |
| Ma, Q | 1 |
| Cai, X | 1 |
| Yang, H | 3 |
| Danforth, RM | 1 |
| Cook, JA | 1 |
| Bennett, WE | 1 |
| Tholpady, SS | 1 |
| Gerety, PA | 1 |
| Belk, JW | 1 |
| McCarty, EC | 1 |
| Houck, DA | 1 |
| Dragoo, JL | 1 |
| Savoie, FH | 1 |
| Thon, SG | 1 |
| Kang, BX | 1 |
| Li, YL | 1 |
| Xu, H | 2 |
| Gao, CX | 1 |
| Zhong, S | 1 |
| Xie, J | 5 |
| Sun, ST | 1 |
| Xu, XR | 1 |
| Zhao, C | 1 |
| Ma, YH | 1 |
| Zhai, WT | 1 |
| Xiao, LB | 1 |
| Hu, XX | 1 |
| Owen, A | 1 |
| Wellings, EP | 1 |
| Wyles, CC | 1 |
| Yuan, BJ | 1 |
| Rose, PS | 1 |
| Houdek, MT | 1 |
| Lei, Y | 1 |
| Huang, Q | 5 |
| Huang, W | 2 |
| Pei, F | 5 |
| Cohen, LL | 1 |
| Przybylski, R | 1 |
| Marshall, AC | 1 |
| Emans, JB | 1 |
| Hedequist, DJ | 1 |
| Shrestha, IK | 1 |
| Ruan, TY | 1 |
| Lin, L | 1 |
| Tan, M | 1 |
| Na, XQ | 1 |
| Qu, QC | 1 |
| Chen, JC | 1 |
| Si, YY | 1 |
| Tao, JP | 1 |
| Reale, D | 1 |
| Andriolo, L | 1 |
| Gursoy, S | 1 |
| Bozkurt, M | 1 |
| Filardo, G | 1 |
| Zaffagnini, S | 1 |
| İpek, HD | 1 |
| Bezgin, SÜ | 1 |
| Çakabay, T | 1 |
| Çelebi, Ş | 1 |
| Choi, YJ | 1 |
| Park, HJ | 1 |
| Lee, HJ | 1 |
| Lee, GY | 1 |
| Kim, WS | 1 |
| Batagello, CA | 1 |
| Vicentini, FC | 1 |
| Monga, M | 1 |
| Miller, AW | 1 |
| Marchini, GS | 1 |
| Torricelli, FCM | 1 |
| Danilovic, A | 1 |
| Coelho, RF | 1 |
| Srougi, M | 1 |
| Nahas, WC | 1 |
| Mazzucchi, E | 1 |
| Burton, H | 1 |
| Mossadegh, S | 1 |
| McCarthy, R | 1 |
| Varady, NH | 1 |
| Chen, AF | 1 |
| Drayer, NJ | 1 |
| Ready, J | 1 |
| Lozano-Calderon, SA | 1 |
| Hayden, BL | 1 |
| Debre, J | 1 |
| Štěpán, Z | 1 |
| Dupal, J | 1 |
| Shi, H | 1 |
| Zhou, ZM | 1 |
| Xu, ZY | 1 |
| Zhu, L | 1 |
| Jiang, ZL | 1 |
| Wu, XT | 1 |
| Ma, J | 3 |
| Lu, H | 1 |
| Chen, X | 2 |
| Wang, D | 2 |
| Wang, Q | 3 |
| Changjun, C | 1 |
| Xin, Z | 1 |
| Yue, L | 1 |
| Chengcheng, Z | 1 |
| Qiuru, W | 1 |
| Qianhao, L | 1 |
| Pengde, K | 1 |
| Madden, A | 1 |
| Hulme, P | 1 |
| Porter, SB | 1 |
| Duncan, CM | 1 |
| Wilke, BK | 1 |
| Wei, H | 1 |
| Xiao, Q | 1 |
| He, J | 1 |
| Huang, T | 1 |
| Xu, W | 1 |
| Xian, S | 1 |
| Xia, M | 1 |
| Liu, X | 1 |
| Liu, J | 2 |
| Sun, G | 1 |
| Mi, B | 1 |
| Liu, G | 1 |
| Zhou, W | 1 |
| Lv, H | 1 |
| Zha, K | 1 |
| Wu, Q | 1 |
| Ghavimi, MA | 1 |
| Taheri Talesh, K | 1 |
| Ghoreishizadeh, A | 1 |
| Chavoshzadeh, MA | 1 |
| Zarandi, A | 1 |
| Zhou, ZF | 1 |
| Zhang, FJ | 1 |
| Huo, YF | 1 |
| Yu, YX | 1 |
| Yu, LN | 1 |
| Sun, K | 1 |
| Sun, LH | 1 |
| Xing, XF | 1 |
| Yan, M | 1 |
| Mehdizadeh, M | 1 |
| Ghassemi, A | 1 |
| Khakzad, M | 1 |
| Mir, M | 1 |
| Nekoohesh, L | 1 |
| Moghadamnia, A | 1 |
| Bijani, A | 1 |
| Mehrbakhsh, Z | 1 |
| Ghanepur, H | 1 |
| Baskaran, D | 1 |
| Rahman, S | 1 |
| Salmasi, Y | 1 |
| Froghi, S | 1 |
| Berber, O | 1 |
| George, M | 1 |
| Wang, Z | 1 |
| Shen, X | 1 |
| Hu, Q | 2 |
| Shimauchi, T | 1 |
| Yamaura, K | 1 |
| Higashi, M | 1 |
| Abe, K | 1 |
| Yoshizumi, T | 1 |
| Hoka, S | 1 |
| Berkowitz, RL | 1 |
| Queiroz, SIML | 1 |
| Silvestre, VD | 1 |
| Soares, RM | 1 |
| Campos, GBP | 1 |
| Germano, AR | 1 |
| da Silva, JSP | 1 |
| Yuan, X | 1 |
| Dorweiler, MA | 1 |
| Boin, MA | 1 |
| Froehle, AW | 1 |
| Lawless, MW | 1 |
| May, JH | 1 |
| Junejo, F | 1 |
| Akhtar, MI | 1 |
| Hamid, M | 1 |
| Ahmed, SS | 1 |
| Minai, F | 1 |
| Amanullah, M | 1 |
| Wallace, SK | 1 |
| Halverson, JW | 1 |
| Jankowski, CJ | 1 |
| DeJong, SR | 1 |
| Weaver, AL | 1 |
| Weinhold, MR | 1 |
| Borah, BJ | 1 |
| Moriarty, JP | 1 |
| Cliby, WA | 1 |
| Kor, DJ | 1 |
| Higgins, AA | 1 |
| Otto, HA | 1 |
| Dowdy, SC | 1 |
| Bakkum-Gamez, JN | 1 |
| Schiavone, A | 1 |
| Bisaccia, M | 1 |
| Inkov, I | 1 |
| Rinonapoli, G | 1 |
| Manni, M | 1 |
| Rollo, G | 1 |
| Meccariello, L | 1 |
| Vicente, CI | 1 |
| Ceccarini, P | 1 |
| Ruggiero, C | 1 |
| Caraffa, A | 1 |
| Liu, Q | 1 |
| Geng, P | 1 |
| Shi, L | 1 |
| Wang, P | 1 |
| Zhu, Q | 1 |
| Yu, C | 1 |
| Xu, X | 1 |
| Chen, Y | 1 |
| Liu, C | 2 |
| Lin, P | 1 |
| Fraval, A | 1 |
| Duncan, S | 1 |
| Murray, T | 1 |
| Duggan, J | 1 |
| Tirosh, O | 1 |
| Tran, P | 1 |
| de Vasconcellos, SJA | 1 |
| do Nascimento-Júnior, EM | 1 |
| de Aguiar Menezes, MV | 1 |
| Tavares Mendes, ML | 1 |
| de Souza Dantas, R | 1 |
| Martins-Filho, PRS | 1 |
| Peck, J | 1 |
| Kepecs, DM | 1 |
| Mei, B | 1 |
| Safir, OA | 1 |
| Backstein, D | 1 |
| Gross, AE | 1 |
| Kuzyk, PR | 1 |
| Lévy, Y | 1 |
| Azar, M | 1 |
| Tran, L | 1 |
| Boileau, P | 1 |
| Bronsard, N | 1 |
| Trojani, C | 1 |
| Dastrup, A | 1 |
| Pottegård, A | 1 |
| Hallas, J | 1 |
| Overgaard, S | 1 |
| Han, X | 1 |
| Gong, G | 1 |
| Han, N | 1 |
| Liu, M | 2 |
| Reichel, F | 1 |
| Peter, C | 1 |
| Ewerbeck, V | 1 |
| Egermann, M | 1 |
| Kim, DH | 1 |
| Kim, S | 1 |
| Kang, H | 1 |
| Jin, HJ | 1 |
| Hwang, SH | 1 |
| McGuire, C | 1 |
| Nurmsoo, S | 1 |
| Samargandi, OA | 1 |
| Bezuhly, M | 1 |
| Sun, H | 2 |
| Deng, L | 1 |
| Chen, K | 1 |
| Li, H | 1 |
| Ning, X | 1 |
| Erdogan, U | 1 |
| Tanik, C | 1 |
| Tanriverdi, O | 1 |
| Gunaldi, O | 1 |
| Yilmaz, I | 1 |
| Arslanhan, A | 1 |
| Ofluoglu, AE | 1 |
| Sun, Q | 1 |
| Zheng, C | 1 |
| Jia, Y | 1 |
| Luo, ZY | 1 |
| Zeng, WN | 1 |
| Zhang, Y | 2 |
| He, F | 1 |
| Chen, A | 1 |
| Pi, B | 1 |
| Jiang, W | 1 |
| Shang, L | 1 |
| Willems, A | 1 |
| De Groote, F | 1 |
| Dumoulin, M | 1 |
| Fils, JF | 1 |
| Van der Linden, P | 1 |
| Spitler, CA | 1 |
| Row, ER | 1 |
| Gardner, WE | 1 |
| Swafford, RE | 1 |
| Hankins, MJ | 1 |
| Nowotarski, PJ | 1 |
| Kiner, DW | 1 |
| Gulabi, D | 1 |
| Yuce, Y | 1 |
| Erkal, KH | 1 |
| Saglam, N | 1 |
| Camur, S | 1 |
| Yang, R | 1 |
| Wu, XD | 1 |
| Xiao, PC | 1 |
| Zhu, ZL | 1 |
| Liu, JC | 1 |
| Li, YJ | 1 |
| Chiang, ER | 1 |
| Chen, KH | 1 |
| Wang, ST | 1 |
| Ma, HL | 1 |
| Chang, MC | 1 |
| Liu, CL | 1 |
| Chen, TH | 1 |
| Chen, G | 2 |
| Zhou, Z | 2 |
| Cao, G | 1 |
| Huang, Z | 1 |
| Alexander, PG | 1 |
| Lin, H | 1 |
| Rutnin, S | 1 |
| Pruettivorawongse, D | 1 |
| Thadanipon, K | 1 |
| Vachiramon, V | 1 |
| Merriman, B | 1 |
| Mayson, K | 1 |
| Sawka, A | 1 |
| Akagami, R | 1 |
| Flexman, AM | 1 |
| Chen, TT | 1 |
| Wang, G | 1 |
| Jiang, SL | 1 |
| Li, LB | 1 |
| Gao, CQ | 1 |
| Ichikawa, J | 1 |
| Kodaka, M | 1 |
| Nishiyama, K | 1 |
| Sato, N | 1 |
| Kubota, S | 1 |
| Nakano, K | 1 |
| Komori, M | 1 |
| Muñoz Gómez, M | 1 |
| Páramo Fernández, JA | 1 |
| Zhou, XD | 1 |
| Tao, LJ | 1 |
| Wu, LD | 1 |
| Georgiadis, AG | 1 |
| Muh, SJ | 1 |
| Silverton, CD | 1 |
| Weir, RM | 1 |
| Laker, MW | 1 |
| Chimento, GF | 1 |
| Huff, T | 1 |
| Ochsner, JL | 1 |
| Meyer, M | 1 |
| Brandner, L | 1 |
| Babin, S | 1 |
| Makhija, N | 1 |
| Sarupria, A | 1 |
| Kumar Choudhary, S | 1 |
| Das, S | 1 |
| Lakshmy, R | 1 |
| Kiran, U | 1 |
| Sjoblom, MD | 1 |
| Busso, VO | 1 |
| Linscott, LL | 1 |
| Sadhasivam, S | 1 |
| Sakallioğlu, Ö | 1 |
| Polat, C | 1 |
| Soylu, E | 1 |
| Düzer, S | 1 |
| Orhan, İ | 1 |
| Akyiğit, A | 1 |
| Irwin, A | 1 |
| Khan, SK | 1 |
| Jameson, SS | 1 |
| Tate, RC | 1 |
| Copeland, C | 1 |
| Reed, MR | 1 |
| Gertler, R | 2 |
| Wiesner, G | 3 |
| Tassani-Prell, P | 1 |
| Martin, K | 3 |
| Gruber, M | 1 |
| Clerico, C | 1 |
| Benatar, M | 1 |
| Dumontier, C | 1 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Tkachenko, AI | 1 |
| Crantford, JC | 1 |
| Wood, BC | 1 |
| Claiborne, JR | 1 |
| Ririe, DG | 1 |
| Couture, DE | 1 |
| Thompson, JT | 1 |
| David, LR | 1 |
| Pinzón-Florez, CE | 1 |
| Vélez Cañas, KM | 1 |
| Díaz Quijano, DM | 1 |
| Valerio, IL | 1 |
| Campbell, P | 1 |
| Sabino, J | 1 |
| Lucas, DJ | 1 |
| Jessie, E | 1 |
| Rodriguez, C | 1 |
| Fleming, M | 1 |
| Ali Shah, MU | 1 |
| Asghar, MI | 1 |
| Siddiqi, R | 1 |
| Chaudhri, MS | 1 |
| Janjua, AM | 1 |
| Iqbal, A | 1 |
| Wei, Z | 1 |
| Hong, SK | 1 |
| Duan, Y | 1 |
| Yin, HM | 1 |
| Bagsby, DT | 1 |
| Samujh, CA | 1 |
| Vissing, JL | 1 |
| Empson, JA | 1 |
| Pomeroy, DL | 1 |
| Malkani, AL | 1 |
| Chin, PL | 1 |
| Moo, IH | 1 |
| Pang, HN | 1 |
| Tay, DK | 1 |
| Chia, SL | 1 |
| Lo, NN | 1 |
| Yeo, SJ | 1 |
| Liu, KL | 1 |
| Chen, IH | 1 |
| Wen, SH | 1 |
| Sargant, N | 1 |
| Roy, A | 1 |
| Simpson, S | 1 |
| Chandrakumaran, K | 1 |
| Alves, S | 1 |
| Coakes, J | 1 |
| Bell, J | 1 |
| Knight, J | 1 |
| Wilson, P | 1 |
| Mohamed, F | 1 |
| Cecil, T | 1 |
| Moran, B | 1 |
| Abolghasemian, M | 1 |
| Huether, TW | 1 |
| Soever, LJ | 1 |
| Drexler, M | 1 |
| MacDonald, MP | 1 |
| Backstein, DJ | 1 |
| Sun, X | 1 |
| Dong, Q | 1 |
| Zhang, YG | 1 |
| Soroceanu, A | 1 |
| Oren, JH | 1 |
| Smith, JS | 1 |
| Hostin, R | 1 |
| Shaffrey, CI | 1 |
| Mundis, GM | 1 |
| Ames, CP | 1 |
| Burton, DC | 1 |
| Bess, S | 1 |
| Gupta, MC | 1 |
| Deviren, V | 1 |
| Schwab, FJ | 1 |
| Lafage, V | 1 |
| Errico, TJ | 1 |
| Akgül, T | 1 |
| Büget, M | 1 |
| Salduz, A | 1 |
| Edipoğlu, İS | 1 |
| Ekinci, M | 1 |
| Küçükay, S | 1 |
| Şen, C | 1 |
| Coomber, R | 1 |
| Porteous, M | 1 |
| Hubble, MJW | 1 |
| Parker, MJ | 1 |
| Martin, DT | 1 |
| Gries, H | 1 |
| Esmonde, N | 1 |
| Diggs, B | 1 |
| Koh, J | 1 |
| Selden, NR | 1 |
| Schreiber, M | 1 |
| Kuang, AA | 1 |
| Jiang, X | 1 |
| Ma, XL | 1 |
| Ma, JX | 1 |
| Myles, PS | 1 |
| Smith, JA | 1 |
| Forbes, A | 1 |
| Silbert, B | 1 |
| Jayarajah, M | 1 |
| Painter, T | 1 |
| Cooper, DJ | 1 |
| Marasco, S | 2 |
| McNeil, J | 1 |
| Bussières, JS | 1 |
| McGuinness, S | 1 |
| Byrne, K | 1 |
| Chan, MT | 1 |
| Landoni, G | 1 |
| Wallace, S | 1 |
| Fígar, A | 1 |
| Mc Loughlin, S | 1 |
| Slullitel, PA | 1 |
| Scordo, W | 1 |
| Buttaro, MA | 1 |
| Yu, SK | 1 |
| Callum, J | 1 |
| Alam, A | 1 |
| Yue, C | 1 |
| Lindvall, G | 1 |
| Sartipy, U | 1 |
| Ivert, T | 1 |
| van der Linden, J | 1 |
| Breuer, T | 2 |
| Wilhelm, M | 1 |
| Schreiber, C | 1 |
| Hess, J | 1 |
| Lange, R | 2 |
| Tassani, P | 2 |
| Nicolau-Raducu, R | 1 |
| Subramaniam, K | 1 |
| Marquez, J | 1 |
| Wells, C | 1 |
| Hilmi, I | 1 |
| Sullivan, E | 1 |
| Karkouti, K | 1 |
| Wijeysundera, DN | 1 |
| Yau, TM | 2 |
| McCluskey, SA | 1 |
| Tait, G | 1 |
| Beattie, WS | 1 |
| Murkin, JM | 1 |
| Falter, F | 1 |
| Granton, J | 1 |
| Young, B | 1 |
| Burt, C | 1 |
| Chu, M | 1 |
| Yadav, SP | 1 |
| Sachdeva, A | 1 |
| Bhat, S | 1 |
| Katewa, S | 1 |
| Nakaigawa, N | 1 |
| Kamata, K | 1 |
| Komatsu, R | 1 |
| Ozaki, M | 1 |
| Hewson, I | 1 |
| Makhmalbaf, P | 1 |
| Street, A | 1 |
| McCarthy, P | 1 |
| Walsh, M | 1 |
| Sander, M | 1 |
| Spies, CD | 1 |
| Martiny, V | 1 |
| Rosenthal, C | 1 |
| Wernecke, KD | 1 |
| von Heymann, C | 1 |
| Bell, D | 1 |
| Almeida, A | 1 |
| Rowland, M | 1 |
| Chevet, I | 1 |
| Remérand, F | 1 |
| Couvret, C | 1 |
| Baud, A | 1 |
| Pouplard, C | 1 |
| Rosset, P | 1 |
| Laffon, M | 1 |
| Fusciardi, J | 1 |
| Knorr, J | 1 |
| Macguill, M | 1 |
| Wahba, A | 2 |
| Vonk, A | 1 |
| Bidstrup, B | 1 |
| Goldstone, AB | 1 |
| Bronster, DJ | 1 |
| Chikwe, J | 1 |
| Muedra, V | 1 |
| Delás, F | 1 |
| Villalonga, V | 1 |
| Gómez, M | 1 |
| Sánchez, F | 1 |
| Llopis, JE | 1 |
| Lecker, I | 1 |
| Orser, BA | 1 |
| Mazer, CD | 2 |
| Kalavrouziotis, D | 1 |
| Voisine, P | 1 |
| Mohammadi, S | 1 |
| Dionne, S | 1 |
| Dagenais, F | 1 |
| Manji, RA | 1 |
| Grocott, HP | 1 |
| Leake, J | 1 |
| Ariano, RE | 1 |
| Manji, JS | 1 |
| Menkis, AH | 1 |
| Jacobsohn, E | 1 |
| Brum, MR | 1 |
| Miura, MS | 1 |
| Castro, SF | 1 |
| Machado, GM | 1 |
| Lima, LH | 1 |
| Lubianca Neto, JF | 1 |
| Seo, JG | 1 |
| Moon, YW | 1 |
| Park, SH | 1 |
| Kim, SM | 1 |
| Ko, KR | 1 |
| Hutton, B | 1 |
| Joseph, L | 1 |
| Fergusson, D | 1 |
| Shapiro, S | 1 |
| Tinmouth, A | 1 |
| Watts, CD | 1 |
| Pusateri, AE | 1 |
| Weiskopf, RB | 1 |
| Bebarta, V | 1 |
| Butler, F | 1 |
| Cestero, RF | 1 |
| Chaudry, IH | 1 |
| Deal, V | 1 |
| Dorlac, WC | 1 |
| Gerhardt, RT | 1 |
| Given, MB | 1 |
| Hansen, DR | 1 |
| Hoots, WK | 1 |
| Klein, HG | 1 |
| Macdonald, VW | 1 |
| Mattox, KL | 1 |
| Michael, RA | 1 |
| Mogford, J | 1 |
| Montcalm-Smith, EA | 1 |
| Niemeyer, DM | 1 |
| Prusaczyk, WK | 1 |
| Rappold, JF | 1 |
| Rassmussen, T | 1 |
| Rentas, F | 1 |
| Ross, J | 1 |
| Thompson, C | 1 |
| Tucker, LD | 1 |
| Pleym, H | 1 |
| Stenseth, R | 1 |
| Bjella, L | 1 |
| Karevold, A | 1 |
| Dale, O | 1 |
| Vanek, T | 1 |
| Jares, M | 1 |
| Fajt, R | 1 |
| Straka, Z | 1 |
| Jirasek, K | 1 |
| Kolesar, M | 1 |
| Brucek, P | 1 |
| Maly, M | 1 |
| Abul-Azm, A | 1 |
| Abdullah, KM | 1 |
| Bremerich, DH | 1 |
| Strametz, R | 1 |
| Kirchner, R | 1 |
| Moritz, A | 1 |
| Zwissler, B | 1 |
| Casati, V | 2 |
| Galli, L | 1 |
| D'Angelo, A | 1 |
| Robertshaw, HJ | 1 |
| Mouton, R | 1 |
| Finch, D | 1 |
| Davies, I | 1 |
| Binks, A | 1 |
| Zacharowski, K | 1 |
| Sabato, AF | 1 |
| Foti, A | 1 |
| De Cosmo, G | 1 |
| Bondoli, A | 1 |
| Lundvall, F | 1 |
| Nielsen, NC | 1 |
| Grundsell, H | 1 |
| Larsson, G | 1 |
| Bekassy, Z | 1 |
| Ottesen, S | 1 |
| Stormorken, H | 1 |
| Hatteland, K | 1 |
| Hedelin, H | 1 |
| Teger-Nilsson, AC | 1 |
| Peterson, HI | 1 |
| Pettersson, S | 1 |
| Syrjänen, SM | 2 |
| Syrjänen, KJ | 2 |
| Pappalardo, G | 2 |
| Caltabiano, M | 2 |
| Bella, G | 2 |
| Cicciù, D | 2 |
| Miller, RA | 1 |
| May, MW | 1 |
| Hendry, WF | 1 |
| Whitfield, HN | 1 |
| Wickham, JE | 1 |
| Smart, CJ | 1 |
| Bewermeyer, H | 1 |
| Szelies, B | 1 |
| Lumenta, C | 1 |
| Heiss, WD | 1 |
| Cousin, MT | 1 |
| Boughenou, F | 1 |
| Madi-Jebara, S | 1 |
| Massonnet-Vastel, S | 1 |
| Benmosbah, L | 1 |
| Fremes, SE | 1 |
| Wong, BI | 1 |
| Lee, E | 1 |
| Mai, R | 1 |
| Christakis, GT | 1 |
| McLean, RF | 1 |
| Goldman, BS | 1 |
| Naylor, CD | 1 |
| Coffey, A | 1 |
| Pittmam, J | 1 |
| Halbrook, H | 1 |
| Fehrenbacher, J | 1 |
| Beckman, D | 1 |
| Hormuth, D | 1 |
| Rousou, JA | 1 |
| Engelman, RM | 1 |
| Flack, JE | 1 |
| Deaton, DW | 1 |
| Owen, SG | 1 |
| Ali, IM | 1 |
| Landymore, RW | 1 |
| Oertli, D | 1 |
| Laffer, U | 1 |
| Haberthuer, F | 1 |
| Kreuter, U | 1 |
| Harder, F | 1 |
| Horrow, J | 1 |
| Strong, MD | 2 |
| Van Riper, DF | 1 |
| Ramström, G | 1 |
| Sindet-Pedersen, S | 1 |
| Hall, G | 1 |
| Blombäck, M | 1 |
| Alander, U | 1 |
| Lindoff, C | 1 |
| Rybo, G | 1 |
| Astedt, B | 1 |
| Ovrum, E | 1 |
| Am Holen, E | 1 |
| Abdelnoor, M | 1 |
| Oystese, R | 1 |
| Ringdal, ML | 1 |
| Katsaros, D | 1 |
| Petricevic, M | 1 |
| Snow, NJ | 1 |
| Woodhall, DD | 1 |
| Van Bergen, R | 1 |
| Howes, JP | 1 |
| Sharma, V | 1 |
| Cohen, AT | 1 |
| Castelli, R | 1 |
| Cicardi, M | 1 |
| Gardinali, M | 1 |
| Zingale, LC | 1 |
| Savi, C | 1 |
| Munari, M | 1 |
| Agostoni, A | 1 |
| Dryden, PJ | 1 |
| O'Connor, JP | 1 |
| Jamieson, WR | 1 |
| Reid, I | 1 |
| Ansley, D | 1 |
| Sadeghi, H | 1 |
| Burr, LH | 1 |
| Munro, AI | 1 |
| Merrick, PM | 1 |
| Hardy, JF | 1 |
| Bélisle, S | 1 |
| Dupont, C | 1 |
| Harel, F | 1 |
| Robitaille, D | 1 |
| Roy, M | 1 |
| Gagnon, L | 1 |
| Benoni, G | 1 |
| Lethagen, S | 1 |
| Nilsson, P | 1 |
| Fredin, H | 1 |
| O'Brien, JG | 1 |
| Battistini, B | 1 |
| Zaharia, F | 1 |
| Plante, GE | 1 |
| Sirois, P | 1 |
| Guzzon, D | 1 |
| Oppizzi, M | 1 |
| Bellotti, F | 1 |
| Franco, A | 1 |
| Gerli, C | 1 |
| Cossolini, M | 1 |
| Torri, G | 1 |
| Calori, G | 1 |
| Benussi, S | 1 |
| Alfieri, O | 1 |
| Ruel, MA | 1 |
| Wang, F | 1 |
| Bourke, ME | 1 |
| Dupuis, JY | 1 |
| Robblee, JA | 1 |
| Keon, WJ | 1 |
| Rubens, FD | 1 |
| Obrant, KO | 1 |
| Gersel-Pedersen, N | 1 |
| Verstraete, M | 2 |
| Tyberghein, J | 1 |
| De Greef, Y | 1 |
| Daems, L | 1 |
| Van Hoof, A | 1 |
| Fodstad, H | 1 |
| Liliequist, B | 1 |
| Schannong, M | 1 |
| Thulin, CA | 1 |
| Ehlers, N | 2 |
| Bramsen, T | 2 |
| Ward, MG | 1 |
| Richards, B | 1 |
| Hedlund, PO | 1 |
| Jerndal, T | 1 |
| Frisén, M | 1 |
| Castelli, G | 1 |
| Vogt, E | 1 |
| Ali, G | 1 |
| Ascanelli, L | 1 |
| Pagliuso, G | 1 |
| Prentice, CR | 1 |
| Valsecchi, A | 1 |
| Cappelletti, M | 1 |
| Carson, S | 1 |
| Weisel, RD | 1 |
| Ivanov, J | 1 |
| Sun, Z | 1 |
| Yu, R | 1 |
| Glynn, MF | 1 |
| Teasdale, SJ | 1 |
| Horrow, JC | 1 |
| Hlavacek, J | 1 |
| Collier, W | 1 |
| Brodsky, I | 1 |
| Goldman, SM | 1 |
| Goel, IP | 1 |
| Tsementzis, SA | 1 |
| Hitchcock, ER | 1 |
| Meyer, CH | 1 |
| Nørrelykke Nissen, J | 1 |
| Auvinen, O | 1 |
| Baer, GA | 1 |
| Nordback, I | 1 |
| Saaristo, J | 1 |
| Razis, PA | 1 |
| Coulson, IH | 1 |
| Gould, TR | 1 |
| Findley, IL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Multicenter, Randomized, Parallel Groups Study Comparing the Safety and the Efficacy of the Administration of One Intra-articular Injection of 4.8 ml (HO-1) or Three Intra-articular Injections of 2.2 ml (HS-3) of Pandora Gel to One Intra-arti[NCT05978180] | 252 participants (Anticipated) | Interventional | 2023-10-18 | Recruiting | |||
| Prospective, Multicenter, Open Study Evaluating the Short-term Safety of Use of Pandora Administered in the Form of 1 Intra-articular Injection of Happyone or 3 Intra-articular Injections of Happysoft in Patients Suffering From Gonarthrosis[NCT05414617] | 20 participants (Actual) | Interventional | 2022-06-08 | Completed | |||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Effects of the Application of a New Pharmacological Protocol for Shoulder Arthroscopy in Beach Chair Position[NCT05397652] | Phase 4 | 104 participants (Actual) | Interventional | 2021-05-24 | Completed | ||
| Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial[NCT02966236] | Phase 4 | 192 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial[NCT05816668] | Phase 3 | 122 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238] | Phase 2 | 130 participants (Anticipated) | Interventional | 2023-04-12 | Recruiting | ||
| Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss, Transfusion Index and Complications After Total Hip Replacement. A Prospective, Randomized, Double Blind Clinical Trial[NCT04187014] | Phase 2 | 90 participants (Actual) | Interventional | 2020-02-06 | Completed | ||
| Comparative Use of Tranexamic Acid Intravenous and Topical Application in the Treatment of Intertrochanteric Fractures With Proximate Femoral Nail[NCT04696224] | 90 participants (Anticipated) | Interventional | 2020-12-18 | Recruiting | |||
| Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis[NCT05774717] | Phase 1 | 60 participants (Anticipated) | Interventional | 2023-04-01 | Recruiting | ||
| Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery[NCT04754230] | Phase 4 | 40 participants (Actual) | Interventional | 2021-06-17 | Completed | ||
| Efficacy of Tranexamic Acid in Femoral Shaft Fractures Osteosynthesis; A Double Blind Randomized Controlled Trial[NCT04803591] | Phase 4 | 0 participants (Actual) | Interventional | 2021-08-01 | Withdrawn (stopped due to Not approved by Ethics Commettee) | ||
| The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408] | Phase 4 | 128 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty[NCT03328832] | Phase 4 | 70 participants (Actual) | Interventional | 2017-09-12 | Completed | ||
| Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty[NCT03825939] | Phase 4 | 52 participants (Actual) | Interventional | 2015-04-21 | Terminated (stopped due to Lack of patient enrollment due to only one surgeon that was enrolling.) | ||
| Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial[NCT02650856] | Phase 3 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Blood-saving Effect of Kaolin-based Hemostatic Gauze Combined With Intravenous Tranexamic Acid in Total Knee Arthroplasty[NCT05504577] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-03-16 | Recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk[NCT02865174] | Phase 4 | 90 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)[NCT02257580] | Phase 4 | 28 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid in Patients at High Risk for Blood Transfusion After Spine Surgery[NCT03849443] | Early Phase 1 | 604 participants (Anticipated) | Interventional | 2019-08-26 | Recruiting | ||
| Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study[NCT03109652] | Phase 4 | 144 participants (Anticipated) | Interventional | 2017-07-10 | Recruiting | ||
| Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty[NCT03359525] | Phase 4 | 114 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815] | Phase 4 | 200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245] | Phase 4 | 100 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153] | 99 participants (Actual) | Interventional | 2018-12-19 | Completed | |||
| Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Seizures After Cardiac Surgery -- A Prospective Study With Continuous EEG Monitoring[NCT01291992] | 100 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| Benefits on Post-operative Pain of Intravenous, Intraoperative, Tranexamic Acid Injection During Arthroscopic Shoulder Surgery.[NCT05302986] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-02-24 | Recruiting | ||
| The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355] | 76 participants (Actual) | Interventional | 2012-06-12 | Completed | |||
| Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children[NCT01228136] | Phase 4 | 95 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.[NCT01850394] | 152 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Efficacy and Safety of Erythropoietin And/Or Intravenous Iron Sucrose For Treatment of Anemia In Hip and Knee Arthroplasty: A Single-center Retrospective Study[NCT03917394] | 780 participants (Anticipated) | Observational | 2019-04-24 | Recruiting | |||
| Role of Topical Tranexamic Acid in Total Hip Arthroplasty[NCT01866943] | Phase 2 | 41 participants (Actual) | Interventional | 2011-11-30 | Terminated | ||
| Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery[NCT05708690] | Phase 4 | 132 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial[NCT01895101] | Phase 4 | 750 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery[NCT01519245] | Phase 3 | 44 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Cardiac Surgery : In Vivo Titration of Protamine[NCT00684450] | 138 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| The Effect of Tranexamic Acid on Intraoperative and Post-Operative Bleeding in Functional Endoscopic Sinus Surgery: A Randomized, Prospective, Double-Blinded Study[NCT00671281] | 74 participants (Anticipated) | Interventional | 2008-10-31 | Withdrawn (stopped due to Study was cancelled) | |||
| Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma[NCT00307606] | Phase 4 | 40 participants (Anticipated) | Interventional | 2005-12-31 | Recruiting | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery[NCT01655641] | Phase 2/Phase 3 | 118 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | ||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
| Evaluation of Tranexamic Acid Prior to Surgery in the Geriatric Hip Fracture Population for the Reduction of Post-Operative Blood Transfusion[NCT03923959] | Phase 3 | 400 participants (Anticipated) | Interventional | 2020-02-01 | Active, not recruiting | ||
| Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973] | Phase 3 | 220 participants (Actual) | Interventional | 2018-12-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Patient-reported Visual Analog Scale - Bleeding Score Day 1. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 1 (assessed within first 24 hours following surgery)
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 5.03 |
| 1,000mg IV Tranexamic Acid | 4.82 |
Patient-reported Visual Analog Scale - Bleeding Score Day 2. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 2
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 4.47 |
| 1,000mg IV Tranexamic Acid | 3.89 |
Patient-reported Visual Analog Scale - Bleeding Score Day 3. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 3
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.93 |
| 1,000mg IV Tranexamic Acid | 2.29 |
Patient-reported Visual Analog Scale - Bleeding Score Day 4. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 4
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 2.12 |
| 1,000mg IV Tranexamic Acid | 1.44 |
Patient-reported Visual Analog Scale - Bleeding Score Day 5. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 5
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.32 |
| 1,000mg IV Tranexamic Acid | 1.15 |
Patient-reported Visual Analog Scale - Bleeding Score Day 6. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 6
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 1.36 |
| 1,000mg IV Tranexamic Acid | 0.76 |
Patient-reported Visual Analog Scale - Bleeding Score Day 7. Score range: 0 (no bleeding) to 10 (uncontrolled bleeding). (NCT04754230)
Timeframe: Postoperative Day 7
| Intervention | score on a scale (Mean) |
|---|---|
| Normal Saline | 0.97 |
| 1,000mg IV Tranexamic Acid | 0.72 |
Number of patients in each arm requiring evaluation by the resident service for bleeding concerns expressed by the recovery nurse (in PACU), had any follow-up visit or phone call outside of regularly scheduled follow-up (NCT04754230)
Timeframe: Day of surgery through 1 week
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| PACU | Follow-up visit | Follow-up phone call | |
| 1,000mg IV Tranexamic Acid | 0 | 1 | 2 |
| Normal Saline | 0 | 0 | 2 |
Patient-reported Visual Analog Scale - Guaze Saturation Score through Postoperative Day 7. Score range: 0 (not at all) to 10 (dripping blood). (NCT04754230)
Timeframe: Postoperative Day 2 through Postoperative Day 7
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Postoperative day 2 | Postoperative day 3 | Postoperative day 4 | Postoperative day 5 | Postoperative day 6 | Postoperative day 7 | |
| 1,000mg IV Tranexamic Acid | 4.56 | 2.09 | 0.76 | 0.40 | 0.29 | 0.28 |
| Normal Saline | 5.16 | 3.03 | 1.74 | 1.11 | 0.99 | 0.80 |
We will record the event of blood transfusion, and calculate the incidence of transfusion (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 1 |
| Topical TXA Alone | 0 |
The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents (NCT03328832)
Timeframe: within 30 days of the operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Combined Topical TXA and Floseal | 0 |
| Topical TXA Alone | 0 |
Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused (NCT03328832)
Timeframe: From the operation to the postoperative day 3 or 4
| Intervention | ml (Mean) |
|---|---|
| Combined Topical TXA and Floseal | 678 |
| Topical TXA Alone | 733 |
Measured in Days (NCT03825939)
Timeframe: At Hospital Discharge
| Intervention | Days (Mean) |
|---|---|
| Intravenous Tranexamic Acid | 3 |
| Intravenous Placebo | 3 |
| Intravenous Tranexamic Acid Followed by Intravenous Placebo | 3 |
The blood quantification will be taken at 6am every day. (NCT02650856)
Timeframe: up to 2nd day post operative (24 and 48 hrs)
| Intervention | mL (Mean) | |
|---|---|---|
| 24 hours | 48 hours | |
| Group 1 Tranexamic Acid | 246.4 | 120.8 |
| Group 2 Platelet Rich Plasma | 263.2 | 140.2 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | percentage of Hematocrite (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 41.7 | 31.6 | 29.1 | 28.6 |
| Group 2 Platelet Rich Plasma | 41.5 | 29.8 | 27.7 | 27.3 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 13.6 | 10.3 | 9.5 | 9.3 |
| Group 2 Platelet Rich Plasma | 13.6 | 9.9 | 9.2 | 9.1 |
Incidence of VTE (symptomatic of DVT or PE), infection (superficial, deep), hematoma, seroma, reoperation, and death, measured in person-years ( x cases per 100,000 person years) (NCT02257580)
Timeframe: an expected average of 1 week (post-surgery), Follow-up at 6 weeks
| Intervention | cases per 100,000 person years (Number) |
|---|---|
| E-Aminocaproic Acid (EACA) | 0 |
| Placebo | 0 |
Determined by estimated blood volume, calculated using difference in preoperative and postoperative hemoglobin and applied to the Nadler equation for estimating blood volume while adjusting for transfused hemoglobin to produce a single metric of calculated intraoperative blood loss. (NCT02257580)
Timeframe: Intraoperative (3-6 hours)
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 535.7 |
| Placebo | 628.0 |
Number of participants requiring 1 unit of intraoperative cell saver transfusion. Patients either received or did not receive intraoperative cell saver transfusion. The maximum number of intraoperative units transfused in this study was 1 unit. The count of participants in the data table refers to the number of patients who received this transfusion. (NCT02257580)
Timeframe: Intraoperative, 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 7 |
| Placebo | 7 |
postoperative day of discharge after surgery- day of intake. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | days (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 5.5 |
| Placebo | 5.1 |
24 hour drain output (mL) (NCT02257580)
Timeframe: Post-Surgery, 24 hours
| Intervention | mL (Mean) |
|---|---|
| E-Aminocaproic Acid (EACA) | 72.5 |
| Placebo | 103.3 |
The number of participants that required 1 unit of blood transfused post-operatively. Patients received blood if necessary post operatively, and the maximum number of units a patient received was 1. The count of participants refers to the number of patients who received this transfusion unit. (NCT02257580)
Timeframe: Post-Surgery, an expected average of 1 week
| Intervention | Participants (Count of Participants) |
|---|---|
| E-Aminocaproic Acid (EACA) | 4 |
| Placebo | 3 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 450 |
| Placebo | 365 |
To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 8 |
| Placebo | 5 |
(NCT01850394)
Timeframe: postoperative period (5 days after surgery)
| Intervention | participants (Number) |
|---|---|
| Control Group | 10 |
| TXA-250 Group | 6 |
| TXA-500 Group | 0 |
Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | g/dL (Mean) |
|---|---|
| Control Group | 2.9 |
| TXA-250 Group | 2.2 |
| TXA-500 Group | 2.2 |
"Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.~Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.~1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.~Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better." (NCT01850394)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Knee Society Knee score at 1 year | WOMAC score at 1 year | |
| Control Group | 148.9 | 15.5 |
| TXA-250 Group | 151.2 | 15.1 |
| TXA-500 Group | 150.9 | 14.5 |
"Postoperative complications were measured as an incidence of the following complications;~wound hematoma~surgical site infection~systemic infection~deep vein thrombosis~pulmonary embolism~knee stiffness requiring manipulation~medical complication such as myocardial infarction, congestive hear failure" (NCT01850394)
Timeframe: postoperative 1-year period
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Re-clamp incidence | Re-dressing incidence | Venous thromboembolic complication | Congestive heart failure | |
| Control Group | 6 | 3 | 4 | 0 |
| TXA-250 Group | 1 | 0 | 1 | 1 |
| TXA-500 Group | 0 | 0 | 2 | 0 |
"Drainage blood loss measured by accumulating total drainage volume postoperatively~Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day" (NCT01850394)
Timeframe: 5 days after surgery
| Intervention | ml (Median) | |
|---|---|---|
| Drainage blood loss | Calculated total blood loss | |
| Control Group | 546.9 | 329.2 |
| TXA-250 Group | 475.0 | 239.7 |
| TXA-500 Group | 430.2 | 217.2 |
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb. (NCT01866943)
Timeframe: Pre Op, Post Op Day 2
| Intervention | Hemoglobin (grams/deciliter) (Mean) |
|---|---|
| Baseline Population | 2.93 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 2 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 65.76 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: 6 week
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 81.77 |
Standardized questionnaire that measures clinical function related to the hip. Total potential range is from 4.0 - 96.0. A higher score indicates a more favorable clinical outcome. (NCT01866943)
Timeframe: Preoperative
| Intervention | units on a scale (Mean) |
|---|---|
| All Study Participants | 58.34 |
Measurement of the thigh at the half way point between the prominence of the greater trochanter and the lateral epicondyle of the femur. No data recorded at 2 weeks or 6 weeks for this study population. (NCT01866943)
Timeframe: Pre Op
| Intervention | centimeters (Mean) |
|---|---|
| Baseline Population | 52.99 |
the secondary objective of this study is to determine whether pericardial lavage with saline gives an improvement in haemostasis, compared with no pericardial lavage, resulting in a reduction of surgical re-explorations and post-operative 12-hour blood loss. The choice for a surgical re-exploration will be decided according to the ICU protocol. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days
| Intervention | participants (Number) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 10 |
| No Pericardial Lavage | 9 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 12 |
The primary study parameter is 12 hours postoperative blood loss and is assessed by postoperative chest tube production. Postoperative chest tube production 12 hours after surgical procedure (NCT01895101)
Timeframe: 12 hours postoperative
| Intervention | ml (Median) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 290 |
| No Pericardial Lavage | 300 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 290 |
The amount of red blood cell transfusions the patient receive pre, peri and postoperatively during their stay in the hospital. (NCT01895101)
Timeframe: participants will be followed for the duration of ICU stay, an expected average of 2 days/ And participants will be followed for the duration of hospital stay, an expected average of 3 weeks
| Intervention | IU (Mean) |
|---|---|
| Pericardial Lavage With 200 ml Normothermic Saline Solution | 0.7 |
| No Pericardial Lavage | 1.1 |
| 2 gr Tranexamic Acid Diluted in 200 ml Normothermic Saline | 0.7 |
Research participants were to receive a blood transfusion in the Intensive Care Unit (ICU) post-operatively if hemoglobin reached a nadir of 80g/L, or at the discretion of the intensivist or cardiac surgeon according to patient clinical status. Transfusion was quantified based on the number of units of PRBC received. (1 unit = 1 bag of blood, as prepared by Canadian Blood Services). Clinical status of research participants was followed throughout their duration in the ICU only. Participation in this study ended upon transfer out of the ICU, to the Cardiology Ward. (NCT01519245)
Timeframe: From ICU admission to transfer to the Cardiology Ward (placebo group = 24.4 hours; trial group = 24.7 hours)
| Intervention | Unit(s) of PRBC (Number) |
|---|---|
| Trial Drug | 0 |
| Placebo | 0 |
According to standard practice, research participants were be transferred to the intensive care unit (ICU) for post-operative monitoring. Measurement of chest tube output began immediately on arrival to the ICU. Hourly measurements were recorded. Data collection ended upon chest tube removal, or return to the operating room for exploratory surgery due to massive blood loss. As per ICU protocol, chest tubes were be removed when blood loss was recorded to be less than 200mL after six consecutive hours. (NCT01519245)
Timeframe: From ICU admission post-operatively to mediastinal chest tube removal (placebo group = 20.6 hours; trial group = 19.8 hours)
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 632 |
| Placebo | 789 |
Volume of chest tube loss at 12 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 12 hours following admission to the Intensive Care Unit
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 464 |
| Placebo | 570 |
Volume of chest tube loss at 6 hours (assuming the total volume of loss is blood). (NCT01519245)
Timeframe: 6 hours following admission to the Intensive Care Unit
| Intervention | mL (Mean) |
|---|---|
| Trial Drug | 342 |
| Placebo | 417 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Median) |
|---|---|
| The Placebo Group | 2 |
| The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | participants (Number) |
|---|---|
| Tranexamic Group | 15 |
| Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Group | 2 |
| Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Number) |
|---|---|
| Tranexamic Group | 38 |
| Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | milliliter (Median) |
|---|---|
| Tranexamic Group | 520 |
| Placebo Group | 730 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
34 reviews available for tranexamic acid and Complication, Postoperative
| Article | Year |
|---|---|
The effect of tranexamic acid in open reduction and internal fixation of pelvic and acetabular fracture: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Fracture Fixation, Internal; Hip Fractures; Humans; P | 2022 |
The effect of tranexamic acid on wound complications in primary total Hip Arthroplasty: A meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Humans; Postoperative Complications; Pulmon | 2020 |
The efficiency and safety of oral tranexamic acid in total hip arthroplasty: A meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; | 2019 |
Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: A GRADE analysis and meta-analysis.
Topics: Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2020 |
Tranexamic Acid Use in Knee and Shoulder Arthroscopy Leads to Improved Outcomes and Fewer Hemarthrosis-Related Complications: A Systematic Review of Level I and II Studies.
Topics: Adult; Anterior Cruciate Ligament Reconstruction; Arthroscopy; Hemarthrosis; Humans; Knee; Lysholm K | 2021 |
The efficacy and safety of high-dose tranexamic acid in adolescent idiopathic scoliosis: a meta-analysis.
Topics: Adolescent; Blood Loss, Surgical; Female; Humans; Infusions, Intravenous; Intraoperative Complicatio | 2021 |
Complications of Tranexamic Acid in Orthopedic Lower Limb Surgery: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Lo | 2021 |
The efficacy and safety of tranexamic acid in high tibial osteotomy: a systematic review and meta-analysis.
Topics: Blood Loss, Surgical; Female; Hemoglobins; Humans; Male; Osteotomy; Postoperative Complications; Saf | 2021 |
A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: A meta-analysis.
Topics: Administration, Cutaneous; Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Repla | 2017 |
Intra-articular versus intravenous tranexamic acid application in total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2017 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
Effect of tranexamic acid use on blood loss and thromboembolic risk in hip fracture surgery: systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Hip Fractures; Humans | 2018 |
The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
Tranexamic acid versus aminocaproic acid for blood management after total knee and total hip arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Repl | 2018 |
Efficacy and Safety of Tranexamic Acid for Blood Salvage in Intertrochanteric Fracture Surgery: A Meta-Analysis.
Topics: Hip Fractures; Humans; Operative Blood Salvage; Postoperative Complications; Thromboembolism; Tranex | 2018 |
Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Schedule; Ecchymosis; Edema; Eyel | 2018 |
Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Arthroplasty, Replacemen | 2018 |
Efficacy of tranexamic acid on operative bleeding in endoscopic sinus surgery: A meta-analysis and systematic review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Endoscopy; Female; Humans; Incidence; Male; Mi | 2019 |
Role of Tranexamic Acid in Reducing Intraoperative Blood Loss and Postoperative Edema and Ecchymosis in Primary Elective Rhinoplasty: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Ecchymosis; Edema; Humans; Postoperative Complication | 2019 |
Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials.
Topics: Administration, Intravenous; Administration, Topical; Anemia; Antifibrinolytic Agents; Arthroplasty, | 2019 |
Does Tranexamic Acid Improve Bleeding, Transfusion, and Hemoglobin Level in Patients Undergoing Multilevel Spine Surgery? A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemoglobins; Humans; Postoperative | 2019 |
Tranexamic acid can reduce blood loss in patients undergoing intertrochanteric fracture surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hematoma; Hemoglobins; Hip Fractur | 2019 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Humans; Postoperative | 2013 |
Efficiency of tranexamic acid in perioperative blood loss in hip arthroplasty: a systematic literature review and meta-analysis.
Topics: Adolescent; Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion; Female; | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Human | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Tranexamic acid and blood loss during and after cesarean section: a meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Volume; Cesarean Section; Fe | 2015 |
Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
Total hip replacement for hip fracture: Surgical techniques and concepts.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Comorbidity; Elective Surgical Procedures; | 2016 |
Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, S | 2016 |
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2012 |
Minimising blood loss and transfusion in contemporary hip and knee arthroplasty.
Topics: Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bl | 2012 |
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Postoperative Complications; Randomized Controlled Tria | 2013 |
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary Artery Byp | 1994 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
72 trials available for tranexamic acid and Complication, Postoperative
| Article | Year |
|---|---|
Use of tranexamic acid in medial open wedge high tibial osteotomy.
Topics: Hemoglobins; Humans; Osteoarthritis, Knee; Osteotomy; Pain, Postoperative; Postoperative Complicatio | 2022 |
Effect of Sequential Intravenous and Oral Tranexamic Acid on Hemoglobin Drop After Total Knee Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antifibrinolytic Agents; Arthroplasty, Repl | 2022 |
Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical | 2023 |
Effect of postoperative tranexamic acid on recurrence rate and complications in chronic subdural hematomas patients: preliminary results of a randomized controlled clinical trial.
Topics: Aged; Drainage; Hematoma, Subdural, Chronic; Humans; Postoperative Complications; Postoperative Peri | 2023 |
Comparison of oral vs. combined topical/intravenous/oral tranexamic acid in the prevention of blood loss in total knee arthroplasty: A randomised clinical trial.
Topics: Administration, Intravenous; Administration, Oral; Administration, Topical; Aged; Antifibrinolytic A | 2019 |
Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial.
Topics: Administration, Intravenous; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Arthroplasty, Replace | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Double-Blin | 2019 |
Combined Application of Dexamethasone and Tranexamic Acid to Reduce the Postoperative Inflammatory Response and Improve Functional Outcomes in Total Hip Arthroplasty.
Topics: Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; C-Reactive | 2020 |
Preoperative erythropoietin within a patient blood management program decreases both blood transfusion and postoperative anemia: a prospective observational study.
Topics: Aged; Anemia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Er | 2020 |
Combined use of intravenous and topical tranexamic acid efficiently reduces blood loss in patients aged over 60 operated with a 2-level lumbar fusion.
Topics: Administration, Topical; Age Factors; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Tra | 2020 |
Tranexamic acid reduces blood cost in long-segment spinal fusion surgery: A randomized controlled study protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female; Human | 2020 |
Prophylactic use of tranexamic acid for prevention of bleeding during transbronchial lung biopsies - A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Antifibrinolytic Agents; Biopsy; Blood Loss, Surgical; Bronchi; Double-Blind Method; Female; H | 2020 |
Effect of Multiple Doses of Intravenous Tranexamic Acid on Perioperative Blood Loss in Total Knee Arthroplasty: A Randomized Controlled Study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2021 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomised, double-blinded, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Blood Vol | 2022 |
Tranexamic acid attenuates early post-operative systemic inflammatory response and nutritional loss and avoids reduction of fibrinogen in total hip arthroplasty within an enhanced recovery after surgery pathway.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Enhanced Recovery Aft | 2021 |
Efficacy of tranexamic acid on side effects of rhinoplasty: A randomized double-blind study.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Ecchymosis; Edema; Female | 2017 |
Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-Rhinoplasty Edema and Ecchymosis.
Topics: Adolescent; Adult; Analysis of Variance; Dexamethasone; Double-Blind Method; Drug Therapy, Combinati | 2018 |
Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Biomarkers; | 2017 |
Tranexamic acid as a local hemostasis method after dental extraction in patients on warfarin: a randomized controlled clinical study.
Topics: Anticoagulants; Antifibrinolytic Agents; Female; Hemostatics; Humans; Male; Middle Aged; Oral Hemorr | 2018 |
Synergistic effects of intravenous and intra-articular tranexamic acid on reducing hemoglobin loss in revision total knee arthroplasty: a prospective, randomized, controlled study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2018 |
Comparison between Intravenous Boluses versus Infusion of Tranexamic Acid (TXA) to Reduce Bleeding in Paediatric Cyanotic Congenital Heart Disease (CHD) Surgeries.
Topics: Administration, Intravenous; Adolescent; Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Cardi | 2018 |
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl | 2019 |
Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Antifibrinolytic Agents; Arthroplasty, Replacement | 2019 |
Tranexamic Acid Use in Open Reduction and Internal Fixation of Fractures of the Pelvis, Acetabulum, and Proximal Femur: A Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Femoral Fractures; | 2019 |
The combined administration of systemic and topical tranexamic acid for total hip arthroplasty: Is it better than systemic?
Topics: Administration, Intravenous; Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, R | 2019 |
Different Effects of Intravenous, Topical, and Combined Application of Tranexamic Acid on Patients with Thoracolumbar Fracture.
Topics: Administration, Intravenous; Administration, Topical; Adult; Antifibrinolytic Agents; Drug Therapy, | 2019 |
Intra-articular Injection of Tranexamic Acid Reduced Postoperative Hemarthrosis in Arthroscopic Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Study.
Topics: Adult; Anterior Cruciate Ligament Reconstruction; Antifibrinolytic Agents; Arthroscopy; Female; Hema | 2019 |
A Prospective Randomized Controlled Study of Oral Tranexamic Acid for the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser for Solar Lentigines.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dermatologic Agents; Double-Blind Method; Drug Admini | 2019 |
Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; China; Comorbidity; Drug Therapy, Combination; Gl | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran | 2013 |
The efficacy of tranexamic acid and corticosteroid on edema and ecchymosis in septorhinoplasty.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration | 2015 |
Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact?
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgica | 2015 |
Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: A double-blinded randomised controlled noninferiority trial.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replace | 2016 |
The Use of a Closed-Suction Drain in Revision Knee Arthroplasty May Not Be Necessary: A Prospective Randomized Study.
Topics: Aged; Arthroplasty; Arthroplasty, Replacement, Knee; Blood Transfusion; Body Mass Index; Drainage; E | 2016 |
Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: A prospective clinical study.
Topics: Administration, Intravenous; Aged; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Tran | 2016 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Component Transfusion; Blood Loss, Surgical; Drug Administ | 2009 |
[Tranexamic acid reduces haematomas but not pain after total knee arthroplasty].
Topics: Aged; Anesthesia, General; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Female; Hematom | 2011 |
Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial.
Topics: Adenoidectomy; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Double-Blind | 2012 |
The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Blood Loss, Sur | 2013 |
Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery Bypass, Off-Pump; Cr | 2005 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
Effect of topical tranexamic acid in open heart surgery.
Topics: Administration, Topical; Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiac Surgical P | 2006 |
[Aprotinin in cardiac surgery: more risks than usefulness?].
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Female; Hemostatics | 2006 |
The hemostatic effect of tranexamic acid in conisatio colli uteri.
Topics: Adult; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dilatation and Curettage; Double-Blind | 1984 |
Use of an antifibrinolytic agent (tranexamic acid) and lateral sutures with laser conization of the cervix.
Topics: Carcinoma in Situ; Cervix Uteri; Clinical Trials as Topic; Curettage; Cyclohexanecarboxylic Acids; F | 1984 |
The effects on extraction wound healing of a new drug combination introduced for use in the prevention of post-extraction complications. A preliminary report.
Topics: Adolescent; Adult; Alveolar Process; Anti-Infective Agents, Local; Antifibrinolytic Agents; Cyclohex | 1981 |
The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Hemorrhage; Humans; Male; Postoperative Compl | 1980 |
[The use of antifibrinolytics in heart surgery. 3 prospective studies].
Topics: Antifibrinolytic Agents; Aprotinin; Blood Platelets; Cardiac Surgical Procedures; Creatinine; Double | 1993 |
The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial.
Topics: Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Doub | 1995 |
Tranexamic acid significantly reduces blood loss associated with coronary revascularization.
Topics: Aged; Blood Coagulation Disorders; Blood Loss, Surgical; Cardiopulmonary Bypass; Erythrocyte Transfu | 1995 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Cardiovascular Diseases; Denta | 1993 |
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.
Topics: Adult; Aged; Blood Transfusion, Autologous; Body Surface Area; Coronary Artery Bypass; Early Ambulat | 1993 |
Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiopulmonary Bypass; Double-Blind Method; Femal | 1996 |
Tranexamic acid reduces blood loss and transfusion in reoperative cardiac surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Blood Transfusion; Blood Volume; C | 1997 |
Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Coronary Artery | 1998 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Metho | 2000 |
Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiac Surgical Proced | 2000 |
Tranexamic acid in alveolar sockets in the prevention of alveolitis sicca dolorosa.
Topics: Adolescent; Adult; Age Factors; Alveolar Process; Contraceptives, Oral; Cyclohexanecarboxylic Acids; | 1979 |
Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy.
Topics: Adenoidectomy; Batroxobin; Benzenesulfonates; Child; Clinical Trials as Topic; Cyclohexanecarboxylic | 1977 |
Tranexamic acid in the preoperative management of ruptured intracranial aneurysms.
Topics: Adult; Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Constriction, Pathologic; Cyclohexan | 1978 |
A double-blind study on the influence of tranexamic acid on the intraocular pressure and the central corneal thickness after trabeculectomy for glaucoma simplex.
Topics: Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Cornea; Cyclohexanecarboxylic Acids; Double | 1978 |
Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test.
Topics: Acute Disease; Aged; Clinical Trials as Topic; Dextrans; Fibrinogen; Heparin; Humans; Male; Middle A | 1975 |
Tranexamic acid (AMCA) and late hyphaema. A double blind study in cataract surgery.
Topics: Administration, Oral; Cataract Extraction; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dr | 1976 |
[Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy].
Topics: Adolescent; Adult; Cyclohexanecarboxylic Acids; Drug Evaluation; Female; Hemorrhage; Humans; Male; M | 1977 |
The effect of warm heart surgery on postoperative bleeding.
Topics: Aminocaproic Acid; Analysis of Variance; Blood Loss, Surgical; Blood Transfusion; Chi-Square Distrib | 1992 |
Prophylactic tranexamic acid decreases bleeding after cardiac operations.
Topics: Adult; Aged; Blood Coagulation Factors; Blood Coagulation Tests; Coronary Artery Bypass; Cyclohexane | 1990 |
Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study.
Topics: Adult; Aged; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials as Topic; Cyclohexanecarbo | 1990 |
No additive effect of tranexamic acid and naproxen on corneal deswelling. A study on oedema after uncomplicated intracapsular cataract extraction with anterior chamber lens implantation.
Topics: Aged; Cataract Extraction; Clinical Trials as Topic; Cornea; Corneal Diseases; Cyclohexanecarboxylic | 1986 |
Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Double-Blind Method; Fibrinoly | 1987 |
112 other studies available for tranexamic acid and Complication, Postoperative
| Article | Year |
|---|---|
Effect of an Elevated Preoperative International Normalized Ratio on Transfusion and Complications in Primary Total Hip Arthroplasty with the Enhanced Recovery after Surgery Protocol.
Topics: Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Transfusion; Enhanced Re | 2022 |
Tranexamic acid protects against implant-associated infection by reducing biofilm formation.
Topics: Animals; Antifibrinolytic Agents; Biofilms; Blood Loss, Surgical; Humans; Mice; Postoperative Compli | 2022 |
Tranexamic Acid Associated With Less Wound Complications in Ankle and Hindfoot Surgery: Level III, Retrospective Cohort Study.
Topics: Ankle; Arthrodesis; Foot; Humans; Postoperative Complications; Retrospective Studies; Tranexamic Aci | 2022 |
[Total hip arthroplasty:topical issues and new concepts].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Humans; Postoperative Complications; Tranex | 2022 |
Effectiveness of prophylactic doses of tranexamic acid in reducing hemorrhagic events in sleeve gastrectomy.
Topics: Gastrectomy; Humans; Laparoscopy; Obesity, Morbid; Postoperative Complications; Postoperative Hemorr | 2022 |
Predictors and complications of blood transfusion in rheumatoid arthritis patients undergoing total joint arthroplasty.
Topics: Antifibrinolytic Agents; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Blood Loss, Surgical | 2023 |
Intravenous tranexamic acid is associated with an increased risk of pulmonary embolism following sarcoma resection.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Postoperative Complications; Pulmonary Emboli | 2023 |
Efficacy of local infiltration of tranexamic acid in subcutaneous surgery: A protocol from a single medical center.
Topics: Fibrinolytic Agents; Hematoma; Humans; Postoperative Complications; Retrospective Studies; Surgeons; | 2023 |
The value of tranexamic acid for patients with preoperative anemia in primary total knee arthroplasty.
Topics: Aged; Anemia; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Chi-Square Distribution; Female | 2019 |
Tranexamic acid and convulsive seizures after off-pump coronary artery bypass surgery: the role of renal insufficiency.
Topics: Adult; Aged; Antifibrinolytic Agents; Coronary Artery Bypass, Off-Pump; Female; Glomerular Filtratio | 2019 |
Postoperative ultrasound evaluation for deep vein thrombosis after knee replacement surgery performed with tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; Humans | 2020 |
What's New in Adult Reconstructive Knee Surgery.
Topics: Analgesics, Opioid; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2020 |
Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Bronchoscopy; Female; Hemoptysis; Hemorrhage; Huma | 2020 |
Simultaneous Bilateral Total Knee Arthroplasty Becomes Safer after Institution of Optimal Perioperative Management: A Longitudinal Cohort Study.
Topics: Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Humans; Longitudinal Studies; Postoperative C | 2021 |
Tranexamic acid and convulsive seizures after isolated coronary artery bypass surgery: the role of cardiopulmonary bypass and renal function.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Glomerular Fi | 2020 |
Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, | 2020 |
Peri-operative administration of tranexamic acid in lower limb arthroplasty: a multicentre, prospective cohort study.
Topics: Aged; Aged, 80 and over; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement; Arthroplasty, R | 2020 |
Consideration on the Use of Tranexamic Acid in Rhytidectomy.
Topics: Double-Blind Method; Humans; Pilot Projects; Postoperative Complications; Rhytidoplasty; Tranexamic | 2020 |
Effect of Tranexamic Acid on Wound Complications and Blood Loss in Total Ankle Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Ankle; Blood Loss, Surgical; Cohort Studie | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Finding the optimal control level of intraoperative blood pressure in no tourniquet primary total knee arthroplasty combine with tranexamic acid: a retrospective cohort study which supports the enhanced recovery strategy.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Pressure | 2020 |
Does tourniquet use decrease blood loss following primary total knee arthroplasty in Jehovah's Witness patients?
Topics: Aged; Anesthesia; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Fe | 2020 |
Is continuation of anti-platelet treatment safe for elective total hip arthroplasty patients?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Aspirin; Blood Los | 2020 |
Tranexamic Acid in Infantile Craniosynostosis Surgery: Friend or Foe?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Craniosynostoses; Female; Humans; | 2020 |
Use of tranexamic acid is not associated with complications following bipolar hemiarthroplasty for metastatic disease.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Femoral Neoplasms; Femur Neck; Follow-Up Stud | 2021 |
Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; C | 2021 |
Surgical Correction of Scoliosis in Children with Severe Congenital Heart Disease and Palliated Single Ventricle Physiology.
Topics: Adolescent; Adult; Child; Cohort Studies; Female; Heart Defects, Congenital; Heart Ventricles; Human | 2021 |
The Effects of Intraoperative Local Tranexamic Acid on Periorbital Edema and Ecchymosis in Septorhinoplasty.
Topics: Ecchymosis; Edema; Humans; Postoperative Complications; Rhinoplasty; Tranexamic Acid | 2021 |
Effect of Tranexamic Acid Administration on Postoperative Ecchymosis and Edema in Excision of Lipomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Dermatologic Surgical | 2021 |
Hockey: a pain in the butt! Isolated superior gluteal artery rupture following blunt pelvic trauma - an unusual case.
Topics: Aneurysm, False; Antifibrinolytic Agents; Buttocks; Computed Tomography Angiography; Embolization, T | 2021 |
Tranexamic acid in patients with current or former cancer undergoing hip and knee arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Fema | 2021 |
[Tranexamic Acid Reduces the Incidence of Heterotopic Ossifications after Elective Primary Total Hip Arthroplasty].
Topics: Arthroplasty, Replacement, Hip; Female; Humans; Incidence; Ossification, Heterotopic; Postoperative | 2021 |
Risk Factors for Increased Surgical Drain Output After Transforaminal Lumbar Interbody Fusion.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Lumbar Verteb | 2021 |
BET 2: Topical tranexamic acid in postcircumcision bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Child, Preschool; Circumcision, Male; Hemorrhage; | 2021 |
Tranexamic Acid Was Not Associated with Increased Complications in High-Risk Patients with Hip Fracture Undergoing Arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Female; Hip | 2021 |
Effect and safety of topical application of tranexamic acid to reduce perioperative blood loss in elderly patients with intertrochanteric fracture undergoing PFNA.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Blo | 2021 |
Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery.
Topics: Adult; Coronary Artery Bypass; Female; Humans; Intraoperative Care; Male; Middle Aged; Postoperative | 2017 |
Fibrinolysis in Living Donor Liver Transplantation Recipients Evaluated Using Thromboelastometry: Impact on Mortality.
Topics: Adult; Aged; Antifibrinolytic Agents; Female; Fibrinolysis; Hepatic Artery; Humans; Incidence; Liver | 2017 |
Commentary on: "Comparison of the Effect of Dexamethasone and Tranexamic Acid, Separately or in Combination on Post-rhinoplasty and Edema and Ecchymosis".
Topics: Dexamethasone; Ecchymosis; Edema; Humans; Osteotomy; Postoperative Complications; Rhinoplasty; Trane | 2018 |
Improved Early Postoperative Range of Motion in Total Knee Arthroplasty Using Tranexamic Acid: A Retrospective Analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies | 2019 |
Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Endometrial Neoplasms; Female; Humans; Laparotomy; | 2018 |
Tranexamic Acid in Pertrochanteric Femoral Fracture: Is it a Safe Drug or Not?
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Transfusion; Female; Fracture Fixation, Intr | 2018 |
The Effect of Preoperative Administration of Intravenous Tranexamic Acid During Revision Hip Arthroplasty: A Retrospective Study.
Topics: Acetabulum; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood | 2018 |
Early morbidity and mortality after single-stage bilateral total knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss | 2018 |
Perioperative Tranexamic Acid Treatment and Risk of Cardiovascular Events or Death After Total Hip Arthroplasty: A Population-Based Cohort Study from National Danish Databases.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Cardiovascular Diseases; Cohort Studi | 2018 |
Reducing Blood Loss in Revision Total Hip and Knee Arthroplasty: Tranexamic Acid Is Effective in Aseptic Revisions and in Second-Stage Reimplantations for Periprosthetic Infection.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Female; | 2018 |
The Efficacy and Safety of Prophylactic Intravenous Tranexamic Acid on Perioperative Blood Loss in Patients Treated with Posterior Lumbar Interbody Fusion.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion, Autologous; Body Mass Index; Bone | 2019 |
Immunohistochemical Grading of Epidural Fibrosis with CD105 Antibody.
Topics: Animals; Antibodies, Monoclonal; Antifibrinolytic Agents; Biomarkers; Endoglin; Epidural Space; Fibr | 2019 |
Aprotinin versus tranexamic acid in children undergoing cardiac surgery: an observational study.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Child, Preschool | 2019 |
The necessity of routine postoperative laboratory tests in enhanced recovery after surgery for primary hip and knee arthroplasty: A retrospective cohort study protocol.
Topics: Adult; Anemia; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, K | 2019 |
Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Erythrocyte Tra | 2019 |
The efficacy and safety of tranexamic acid for reducing blood loss following simultaneous bilateral total knee arthroplasty: a multicenter retrospective study.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2019 |
Postoperative seizure in a neurosurgical patient: Should tranexamic acid be on the differential?
Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic | 2013 |
[A case of postoperative convulsive seizure following tranexamic acid infusion during aortic valve replacement].
Topics: Aged, 80 and over; Aortic Valve; Humans; Male; Postoperative Complications; Seizures; Tranexamic Aci | 2013 |
[Intravenous administration of tranexamic acid to decrease bleeding and transfusion in knee and hip prosthetic surgery: is it safe and cost-effective?].
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Cost-Benefit | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
An evaluation of the use of topical tranexamic acid in total knee arthroplasty.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, | 2013 |
Postoperative cerebral arterial thrombosis following cranial surgery in an infant.
Topics: Antifibrinolytic Agents; Cerebral Angiography; Craniosynostoses; Craniotomy; Humans; Infant; Intracr | 2013 |
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2013 |
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2013 |
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2013 |
Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antifibrinolytic | 2013 |
Measurement of tranexamic acid serum concentrations in a 7-month-old infant with clinical seizures after open heart surgery.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Humans; Infant; Postoperative Complications; S | 2014 |
Radial artery pseudoaneurysm: a rare complication after arthroscopic treatment of a volar wrist ganglion in a hemophilia patient.
Topics: Adult; Aneurysm, False; Antifibrinolytic Agents; Arthroscopy; Ganglion Cysts; Hemophilia A; Humans; | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
[Changes of the hemostasis system in patients with obturation jaundice caused by choledocholithiasis, and possibilities of their correction with the help of miniinvasive operative interventions].
Topics: Anticoagulants; Antifibrinolytic Agents; Blood Coagulation Disorders; Choledocholithiasis; Drug Admi | 2014 |
Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Child, Preschool; Cohort Studies; | 2015 |
TXA in combat casualty care--does it adversely affect extremity reconstruction and flap thrombosis rates?
Topics: Adult; Antifibrinolytic Agents; Arm Injuries; Female; Follow-Up Studies; Free Tissue Flaps; Humans; | 2015 |
Tranexamic Acid Decreases Incidence of Blood Transfusion in Simultaneous Bilateral Total Knee Arthroplasty.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfus | 2015 |
Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: A population-based study in Taiwan.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood L | 2017 |
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Blood Component Transfusion; Blood Loss, Surgical; Cytoreduction Surgical Procedures; Factor VIII; F | 2016 |
Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Humans; Male; | 2016 |
Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Hemorrhage; Humans; Infant; Postope | 2016 |
Influence of single-dose intravenous tranexamic acid on total hip replacement : A study on transfusions, collateral complications, and readmissions.
Topics: Aged; Antifibrinolytic Agents; Argentina; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Bloo | 2017 |
C1-esterase inhibitor for short-term prophylaxis in a patient with hereditary angioedema with normal C1 inhibitor function.
Topics: Adult; Angioedemas, Hereditary; Antifibrinolytic Agents; Complement C1 Inactivator Proteins; Complem | 2016 |
Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.
Topics: Acute Kidney Injury; Aged; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; | 2008 |
Safety and efficacy of tranexamic acid compared with aprotinin in thoracic aortic surgery with deep hypothermic circulatory arrest.
Topics: Antifibrinolytic Agents; Aortic Diseases; Aprotinin; Blood Transfusion; Circulatory Arrest, Deep Hyp | 2010 |
The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Proc | 2010 |
Successful control of massive gastrointestinal bleeding following umbilical cord blood transplantation (UCBT) by use of recombinant activated factor VII (rFVIIa) and octreotide infusion.
Topics: beta-Thalassemia; Bone Marrow Transplantation; Cord Blood Stem Cell Transplantation; Delayed Graft F | 2010 |
[Perioperative management of a patient complicated with Quincke's edema].
Topics: Aneurysm, Ruptured; Angioedema; Chlorpheniramine; Craniotomy; Humans; Intracranial Aneurysm; Intubat | 2010 |
Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Blood Coagulation Factors; Cellulos | 2011 |
Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Cardiop | 2010 |
Tranexamic Acid in cardiac surgery and postoperative seizures: a case report series.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cohort Studies; Coron | 2010 |
Seizures after open heart surgery: comparison of ε-aminocaproic acid and tranexamic acid.
Topics: Aged; Aminocaproic Acid; Anesthesia; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical | 2011 |
Conference discussion: Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Cardiopulmonary Bypass; | 2011 |
Seizures after adult cardiac surgery.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Cardiac Surgical Procedures; Female; Humans; Male; Posto | 2011 |
[Transfusion requirements, morbidity and mortality in cardiac surgery and the use of antifibrinolytic agents: a comparison of aprotinin and tranexamic acid].
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Cross-Sect | 2011 |
"Seizing" the opportunity to understand antifibrinolytic drugs.
Topics: Cardiac Surgical Procedures; Female; Humans; Male; Postoperative Complications; Seizures; Tranexamic | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass.
Topics: Aged; Antifibrinolytic Agents; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Electroence | 2012 |
Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antifibrinolytic Agents; Cardiac Surgical Procedures; Coho | 2012 |
Tranexamic acid and coronary surgery.
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Coronary Vessels; Humans; Intraoperative Compl | 2004 |
Aprotinin and renal risk in cardiac surgery.
Topics: Aprotinin; Cardiac Surgical Procedures; Hemostatics; Humans; Kidney; Postoperative Complications; Ri | 2006 |
An anti-inflammatory role for tranexamic acid in cardiac surgery?
Topics: Antifibrinolytic Agents; Cardiac Surgical Procedures; Cytokines; Humans; Inflammation Mediators; Pos | 2008 |
Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surg | 2008 |
[Coagulative changes in gynecologic surgery. Clinical and therapeutic evaluation].
Topics: Adult; Aged; Anesthesia; Aprotinin; Blood Coagulation Disorders; Disseminated Intravascular Coagulat | 1980 |
The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation.
Topics: Aged; Antithrombin III; Blood Coagulation Tests; Coronary Artery Bypass; Dose-Response Relationship, | 1984 |
Effects of tranexamic acid and local fibrin deposition of fibrinolysis and granulation tissue formation in preformed cavities.
Topics: Animals; Cyclohexanecarboxylic Acids; Drug Evaluation, Preclinical; Drug Implants; Fibrin; Fibrinoly | 1984 |
A new combination of drugs intended to be used as a preventive measure for the postextraction complications. A preliminary report.
Topics: Adolescent; Adult; Cyclohexanecarboxylic Acids; Dibucaine; Drug Combinations; Dry Socket; Humans; Hy | 1981 |
[Behavior of tranexamic acid as an antiflogistic in oral surgery].
Topics: Anti-Inflammatory Agents; Cyclohexanecarboxylic Acids; Humans; Mouth Diseases; Postoperative Complic | 1981 |
The use of frusemide and epsilon-amino-caproic-acid in transurethral prostatectomy. a review after 7 years.
Topics: Aged; Aminocaproates; Aminocaproic Acid; Furosemide; Hemorrhage; Humans; Male; Postoperative Complic | 1982 |
[Changes in the course after spontaneous subarachnoid hemorrhage from the neurological point of view].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Postoperative Complications; Subarachnoid Hemorrhage | 1982 |
The use of tranexamic acid in cardiac operations.
Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative | 1994 |
Tranexamic acid after bypass: too late to help?
Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Complications; Tra | 1994 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Tranexamic acid reduces blood loss after knee arthroplasty.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Knee Prosthesis; Postoperative Complications; | 1996 |
Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency.
Topics: Aged; Anabolic Agents; Angioedema; Antifibrinolytic Agents; Aprotinin; Autoimmune Diseases; Calcium | 1997 |
Effects of tranexamic acid and aprotinin, two antifibrinolytic drugs, on PAF-induced plasma extravasation in unanesthetized rats.
Topics: Animals; Antifibrinolytic Agents; Aorta; Aprotinin; Bronchi; Capillary Leak Syndrome; Capillary Perm | 2000 |
Is tranexamic acid safe in patients undergoing coronary endarterectomy?
Topics: Aged; Coronary Artery Bypass; Coronary Artery Disease; Endarterectomy; Female; Graft Occlusion, Vasc | 2001 |
Transurethral electroresection of prostatic adenoma. Early results.
Topics: Aged; Blood Transfusion; Electrosurgery; Humans; Male; Middle Aged; Postoperative Complications; Pro | 1976 |
Management of late corneal graft problems.
Topics: Adrenal Cortex Hormones; Adult; Aged; Corneal Transplantation; Cyclohexanecarboxylic Acids; Female; | 1978 |
Complications of antifibrinolysis therapy after prostatectomy.
Topics: Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Male; Postoperative Complications; Prostatectomy; | 1979 |
[Preventive use of AMCHA in tonsillectomies under general anesthesia. Clinical evaluation].
Topics: Adolescent; Adult; Anesthesia, General; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug E | 1976 |
[Possibilities of the use of an inhibitor of hemolysis (AMCHA), by rectal and vaginal administration, for gynecological hemorrhages].
Topics: Adolescent; Adult; Aged; Blood Coagulation Disorders; Child; Cyclohexanecarboxylic Acids; Female; He | 1975 |
Acquired C1 esterase inhibitor deficiency.
Topics: Angioedema; Complement C1 Inactivator Proteins; Female; Humans; Mesenteric Vascular Occlusion; Middl | 1986 |
[Further clinical experimental research on the anti-inflammatory action of tranexamic acid in oral surgery].
Topics: Anti-Inflammatory Agents; Cefazolin; Cyclohexanecarboxylic Acids; Humans; Mouth; Postoperative Compl | 1985 |